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Abstract 
Polybrominated Diphenyl Ethers (PBDEs) are flame retardants widely used within the 
United States in various products such as plastics, electronics, textiles and furniture. With an 
increase in production and usage, PBDEs have recently emerged as a contaminant of concern. Due 
to their chemical structure, PBDEs have the propensity to bioaccumulate in mammals. In fact, 
elevated PBDE concentrations have been recorded in human breast milk. Due to the potential 
widespread exposure to PBDEs, this study investigates human blood concentrations of PBDEs 
generated through the 2003-2004 National Health and Nutrition Examination Survey. Through the 
use of statistical modeling, a comparison of mean PBDE concentrations in ng/g lipid is conducted 
based on age, gender and ethnicity. From a sample of 2337 individuals, the average blood 
concentration of PBDEs was approximately 81 ng/g lipid. The average PBDE concentration of 
males was significantly higher than females, using a 95% confidence level. In addition, PBDEs 
detected in human blood ranged approximately from 0.05 to 3676 ng/g lipid, with the highest 
concentrations found in black males. Also, a logistic regression analysis is conducted to determine 
whether an increase in background PBDE concentrations is a risk factor for obesity. Furthermore, 
the analyses of PBDEs are repeated for phthalates and polychlorinated Biphenyls for comparison. 
Finally, the measured concentrations of PBDEs are also compared to health outcome data known 
to show potential risk. 
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Chapter 1 
Introduction 
1.1 Flame Retardants 
In 2009, the National Fire Protection Association reported an estimated 1,348,500 fires in 
the United States. These fires were responsible for approximately 17,050 civilian injuries, 3,010 
civilian deaths and over $12 billion in property damage. Many of the casualties included children 
and the disabled. Unfortunately, the various threats of fires have always been a concern throughout 
history (American Chemistry Council, 2017). As a result, fire protection is a very important aspect 
of emergency planning. There are various methods of fire response and prevention. Within the 
United States, many entities share a responsibility to protect citizens from fire hazards. A city fire 
department is a popular example. However, a lesser-known yet very impactful entity includes the 
chemical industry. For many decades, the chemical industry has been responsible for generating 
compounds combat the progression of fire. These chemicals are called flame retardants (United 
States Environmental Protection Agency [USEPA], 2014). 
 
The term “flame retardant” does not refer to a group of chemicals but, instead, refers to a 
function. Some chemicals with varying structures and properties can function as flame retardants 
and are sometimes combined for greater effect (American Chemistry Council, 2017; ATSDR, 
2017; USEPA, 2014). Flame retardants are usually described as inorganic, halogenated 
compounds often containing bromine, chlorine, phosphorus or nitrogen. By lacing various 
consumer goods with flame retardants, the progression of fire is delayed or prevented. Generally, 
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ignition is prevented by increasing the threshold necessary to start a fire which delays flashover 
and reduces the spread of fire (American Chemistry Council, 2017).  
 
Flame retardant use is an innovative way to protect ourselves from injury, death and 
prevent property damage. It is important to note that over three decades ago, American residents 
had approximately seventeen minutes to escape a house fire, while today, residents have three to 
four minutes. This is largely due to the types of materials used to build today’s household furniture 
in comparison to thirty years ago. Then, more natural materials were used while today’s furniture 
contain more synthetic material that are more flammable (Davis, 2016). This further accentuates 
the need for flame retardants in today’s household goods.  
 
The first flame retardants used in the United States were polychlorinated biphenyls (PCBs). 
However, due to human health concerns, PCB production was banned in 1979. PCBs have been 
classified as carcinogenic to humans (group 1) by the International Agency for Research on Cancer 
(IARC) and are known as persistent organic pollutants. As a result, PCBs were replaced as flame 
retardants by a compound with similar properties known as polybrominated diphenyl ethers 
(PBDEs) (Vonderheide et al., 2008). After 1979, PBDE compounds were the major group of flame 
retardants due to their cost effectiveness. In recent years, there has been a growing concern 
pertaining to the potential environmental and public health risks of background PBDE levels 
(Alaee et al., 2003; Aylward et al., 2013; Banasik et al., 2009; Birnbaum et al., 2004; Castorina et 
al., 2011; Turyk et al., 2009; Vasiliu et al., 2006).  
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1.2 Polybrominated Diphenyl Ethers 
Polybrominated diphenyl ethers are flame retardants used in a variety of appliances, 
fixtures, furniture and other household goods. The use of these chemicals has increased 
tremendously since the ban of PCBs. Just as PCBs and PBDEs share similar flame retardant 
properties, they also share similarities in chemical structure. PBDEs are not covalently bonded to 
the polymer matrix within materials in which they are used. Therefore, these brominated 
compounds are known to readily leach into the surrounding environment where they have shown 
resistance to various forms of biodegradation. They have been shown to bioaccumulate in the food 
chain (Costa & Giordano, 2007; Kiviranta et al., 2004; Turyk et al. 2015; Viberg et al., 2003). 
Lower brominated congeners tend to be more persistent and bioaccumulate more than higher 
brominated congeners. BDE congeners differ in the orientation or total number of bromine atoms 
attached to the ether molecule (ATSDR, 2017).  
 
There are 209 possible congeners. Of these, BDE-47 and BDE-99 make up 75% of the total 
brominated flame retardants in commercial mixtures. In comparison to BDE-47, there is twice as 
much BDE-99 in these commercial mixtures. When congeners contain the same number of 
bromine atoms, they are referred to as homologs. There are ten homologous groups of PBDEs; 
three of which are produced commercially. These three homologs are: decabromodiphenyl ether 
(decaBDE), octabromodiphenyl ether (octaBDE) and pentabromodiphenyl ether (pentaBDE). 
DecaBDE has been the most widely used homolog worldwide (USEPA, 2014).  
 
At the end of 2004, pentaBDE and octaBDE mixtures were voluntarily phased out by their 
only U.S. manufacturers. According to the Environmental Protection Agency, as of January 2014, 
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PBDEs are no longer produced nor imported in the United States (ATSDR, 2017). However, levels 
of PBDEs in breast milk have significantly increased in the United States. In fact, just as usage of 
PBDEs continued to increase, so did the average concentration of PBDEs in humans. The latter 
occurs because PBDEs remain ubiquitous in various products, especially in indoor environments. 
Thus, despite being no longer produced or imported, PBDEs will persist for many years in our 
environment. In addition, PBDEs will likely be present in human tissue and body fluids at elevated 
levels for years to come (Darnerud et al., 2001; Frederiksen et al., 2009; Hooper & McDonald, 
2000; Schecter et al., 2003).  
 
Due to the relatively elevated levels of PBDEs found in human breast milk, in comparison 
to other regions such as Europe (e.g., France, Germany, and Russia), there is increasing concern 
for pregnant mothers and nursing children as they may be more vulnerable to potential health 
effects of PBDEs, which are known to disrupt the body’s endocrine system and thyroid hormone 
levels (Darnerud et al., 2001). Since they are lipophilic, PBDEs tend to accumulate in human fatty 
tissues (USEPA, 2014). As a result, it is important to investigate the level of association between 
their background concentrations and obesity. An investigation of the concentration and distribution 
of PBDEs in the American population is critical to characterizing levels of risk per demographic 
category.  
  
1.3 Phthalates & Dioxin-Like Polychlorinated Biphenyls 
There are dioxin-like and non-dioxin-like PCBs. Non-dioxin-like PCBs are often referred 
to as indicator-PCBs and include some mono-ortho-substituted biphenyls. Some PCBs are 
described as dioxin-like chemicals because they act in the body through similar mechanisms as 
  5 
dioxins (ATSDR, 2000). As previously mentioned, PBDEs and PCBs (especially dioxin-like 
PCBs) share key similarities including their flame retardant properties and chemical structures. 
However, they also share other attributes along with phthalates. While American PBDE production 
and importation have reportedly ceased, and although PCBs have been banned in the United States, 
phthalates are still in use (ATSDR, 2000; ATSDR, 2002; ATSDR, 2017). Like PBDEs and dioxin-
like PCBs (dl-PCBs), phthalates are ubiquitous in our surroundings. Phthalates are used in 
detergents, adhesives, lubricating oils, plastic clothing, containers and personal-care products, just 
to name a few (ATSDR, 2002). All three compounds can be found in household dust. Therefore, 
we are constantly exposed to these chemicals. In addition, PBDEs, dl-PCBs and phthalates are all 
known as potential endocrine disrupting compounds and are lipophilic. All three compounds have 
garnered significant attention concerning their potential human health effects (ATSDR, 2000; 
ATSDR, 2002; ATSDR, 2017; Aylward et al., 2013). Although this research primarily focuses on 
characterizing exposure levels and potential human health effects of PBDEs, it is also pertinent to 
compare results of PBDE analyses with those of PCBs and phthalates. The differences and 
similarities of these results will be discussed.  
 
1.4 Objectives 
This research study investigates the distribution of Polybrominated Diphenyl Ether 
concentrations in American blood using various demographic attributes through the 2003-2004 
National Health and Nutrition Examination Survey (NHANES). The objectives of the current 
study are comprised of the following: 
o Characterize the background concentrations of PBDEs in the blood of 2003-2004 
NHANES participants. 
  6 
o Compare the PBDE blood concentrations between various demographic groups 
including genders, age groups, ethnicities; and, genders and ethnicities (e.g., Black 
Males vs. Mexican American Females). 
o Since PBDEs have a strong affinity for lipids and bioaccumulate in human adipose 
tissue, investigate their association with obesity. 
§ Similarly, the association between PBDE concentrations and being 
overweight is also investigated. 
• Repeat analyses for other lipophilic compounds including phthalates 
and dioxin-like PCBs. 
• Discuss results for the aforementioned objectives in relation to those 
of phthalates and dioxin-like PCBs. 
 
PBDEs are a relatively new compound whose usage significantly increased over time 
(ATSDR, 2017). Much research remains to be done to fully understand their characteristics, 
distribution and potential human health effects. Therefore, these findings will provide a 
significant contribution to the overall body of knowledge for PBDEs. 
 
1.5 Hypotheses 
According to the objectives of this study, the following hypotheses will be tested: 
1. Biomonitoring data obtained from the National Health and Nutrition Examination 
Survey indicates the presence of background biomarkers of PBDE, dl-PCB, and 
phthalate exposure in individuals from a sample of the general population. 
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2. Due to the bioaccumulative properties of PBDEs in the human body, increasing 
PBDE concentrations are significantly associated with increasing with age groups. 
a. Due to the bioaccumulative properties of dl-PCBs in the human body, 
increasing dl-PCB concentrations is significantly associated with increasing 
with age groups. 
b. Due to the bioaccumulative properties of phthalates in the human body, 
increasing phthalate concentrations is significantly associated with 
increasing with age groups. 
3. Since PBDEs are ubiquitous in the environment, the average concentrations of its 
biomarkers are homogeneous across other sample subgroups including genders, 
ethnicities, and, genders and ethnicities; indicating that these subgroups are not at 
an increased risk of a negative health outcome. 
a. Similarly, average dl-PCB concentrations are homogeneous across other 
sample subgroups including genders, ethnicities, and, genders and 
ethnicities; indicating that these subgroups are not at an increased risk of a 
negative health outcome. 
b. Similarly, average phthalate concentrations are homogeneous across other 
sample subgroups including genders, ethnicities, and, genders and 
ethnicities; indicating that these subgroups are not at an increased risk of a 
negative health outcome. 
4. Blood sample data from the National Health and Nutrition Examination Survey 
reveal that the background concentrations of PBDEs do not significantly increase 
the odds of obesity nor the odds of being overweight. 
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a. Blood sample data from the National Health and Nutrition Examination 
Survey reveal that the background concentrations of dl-PCBs do not 
significantly increase the odds of obesity nor the odds of being overweight. 
b. Blood sample data from the National Health and Nutrition Examination 
Survey reveal that the background concentrations of phthalates do not 
significantly increase the odds of obesity nor the odds of being overweight. 
5. Due to the similarities of PBDEs and dl-PCBs, average concentrations are not 
significantly different among demographic categories. 
a. Although distributions of phthalate concentrations can be discussed in 
relation to PBDEs, specific comparisons cannot be made due to a difference 
in measurement units (ng/g lipids for PBDEs and dl-PCBs vs. ng/mL for 
phthalates).  
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Chapter 2 
Literature Review 
2.1 Brominated Flame Retardant Use  
The use of PBDEs began in the late 1970s. Their commercial production began largely as 
a response to the ban of PCBs, which were also used as flame retardants. Due to mounting 
environmental health concerns, PCBs were no longer produced in the United States. As a result, 
the production and usage of other flame retardants such as PBDEs became more prevalent. In fact, 
since the ban of PCBs, there has been a significant augmented use of PBDEs (ATSDR, 2017). In 
2001, the global production rate of PBDEs was over 67,000 tons per year, as shown in Table 1 
(Birnbaum, & Staskal, 2004). By 2003, approximately 98% of the global demand for pentaBDE 
occurred in North America (Hale et al., 2003). However, largely due to unsubstantiated public 
health concerns, PBDEs are also no longer in production in the United States. At the end of 2004, 
the only manufacturers of pentaBDEs and octaBDEs voluntarily phased out their production. As 
the only remaining PBDE mixture marketed for commercial products, decaBDEs experienced a 
similar fate. The only American manufacturers of decaBDEs were Albermarle Corporation and 
Chemtura Corporation; and their largest importer was ICL Industrial Products, Inc. In 2009, all 
three companies guaranteed a voluntary phase out of PBDE manufacture and importation for 
nearly all uses in America by December 31st of 2012. They also guaranteed a complete phase out 
of manufacture and importation for all uses of PBDEs in America by the end of the year 2013 
(ATSDR, 2017).  
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Table 1. Major Brominated Flame Retardant Volume (metric tons) estimates by region in 2001 
(Birnbaum & Staskal 2004). 
 
 
 
During periods of production, PBDEs were used as flame retardants in a variety of 
materials including thermos plastics. PBDEs were physically added to these materials instead of 
being chemically combined. Since PBDEs were not covalently bonded to many of the materials 
they were used for, these chemicals could easily diffuse out of the materials (Siddiqi et al., 2003). 
The furniture industry found great use in pentaBDEs as flame retardants (Standen, 2013). In fact, 
over 95% of pentaBDE commercial mixture usage was in furniture. Specifically, pentaBDEs were 
predominantly used in flexible polyurethane foams which are found in mattresses, sofas, carpets, 
etc. The majority of furniture treated with pentaBDEs were sold in California (ATSDR, 2017). It 
is the only state that required, by law, that upholstered products contain an approved level of 
ignition resistance (Standen, 2013). Only a small percentage of pentaBDEs were used for other 
materials like adhesives, printed circuit board components, hydraulic fluids, and rubber products. 
OctaBDEs were predominantly used as flame retardants in the plastic industry and specifically for 
acrylonitrile-butadiene-styrene terpolymers, often used in computer monitors and casings. 
DecaBDE mixtures were used as additive flame retardants for many polymer applications. The 
primary use of decaBDEs was high impact polystyrene often used as cabinet backs in the television 
industry (ATSDR, 2017; Watanabe & Sakai 2003). 
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2.2 Regulations & Guidelines         
Although PBDEs are no longer being produced or imported in the U.S., the relatively 
limited US regulations and guidelines continue to apply since many products currently used still 
contain PBDEs. The Occupational Safety & Health Administration (OSHA) has not formulated 
any occupational regulations for these flame retardants. The US Food & Drug Administration 
(FDA) has not set any allowable bottled water limits for PBDEs. Also, the International Agency 
for Research on Cancer (IARC) has classified PBDEs as Group 3 toxicants - not classified as 
human carcinogens (Standen, 2013). The Agency for Toxic Substances and Disease Registry 
(ATSDR) has generated Minimum Risk Levels (MRLs) for these brominated flame retardants. 
Based on a no-observed-adverse-effect-level for thyroid hormone effects in rats, an intermediate-
duration inhalation MRL of 0.006 mg/m3 has been generated for lower-brominated congeners. 
Also, based on a lowest-observed-adverse-effect-level for endocrine effects in female rats, and 
neurobehavioral and reproductive effects in F1 offspring from several reports, the ATSDR has 
derived an acute-duration oral MRL of 0.00006 mg/kg/day for lower-brominated congeners 
(ATSDR, 2017). Moreover, based on a negligible lowest-observed-adverse-effect-level for 
decreased testosterone in rats, an intermediate-duration oral MRL of 0.000003 mg/kg/day was 
generated for lower-brominated PBDEs. The ATSDR has also derived an acute-duration oral MRL 
of 0.01 mg/kg/day for decaBDE due to a no-observed-adverse-effect-level for neurobehavioral 
health effects found in rats. In addition, based on a negligible lowest-observed-adverse-effect-level 
for increased serum glucose found in a study of rats, an intermediate-duration oral MRL of 0.0002 
mg/kg/day was derived for decaBDE (ATSDR, 2017; Standen, 2013). The Environmental 
Protection Agency (EPA) has not assigned a reference concentration (RfC) for PBDEs. The EPA 
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has not generated drinking water standards for PBDEs. Instead, the US EPA has generated 
reference doses (RfDs) for PBDEs. The following are the current RfDs for BDE congeners. (IRIS, 
2003; IRIS, 2004; IRIS, 2008a-d). 
• Penta-BDE: 2x10-3mg/kg/day (IRIS, 2004) 
• Octa-BDE: 3x10-3mg/kg/day (IRIS, 2003) 
• Deca-BDE: 7x10-3mg/kg/day (IRIS, 2008a) 
• 2,2’,4,4’-tetraBDE: 1x10-4mg/kg/day (IRIS, 2008b) 
• 2,2’,4,4’,5-pentaBDE: 1x10-4mg/kg/day (IRIS, 2008c) 
• 2,2’,4,4’,5,5’-hexaBDE: 2x10-4mg/kg/day (IRIS, 2008d) 
For all RfDs, potential effects to the nervous system is of significant concern, with a 
potential for neurobehavioral health effects; despite a relatively low level of confidence. Finally, 
mono-BDE congeners are regulated under the Comprehensive Environmental Response, 
Compensation, and Liability Act and Resource Conservation and Recovery Act (ATSDR, 2017). 
 
2.3 Exposure Assessment        
An exposure is defined as an interaction with the skin or eyes or contact through breathing 
or swallowing. This contact can be short-term or acute. On the other hand, it can also be long-term 
or chronic. It should be remembered that an exposure is only an opportunity for absorbing a 
substance. The types and duration of an exposure are key determinants of a significant dose. Then, 
if this dose is significant, there may be a health effect. Exposure assessment is the process of 
determining how someone may come into contact with a toxicant by considering the exposure 
route, frequency, duration and amount of the toxicant. There are several assessment methods which 
depend on the kind of exposure in question. Exposure assessments are commonly used in 
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environmental and occupational settings (Aylward et al. 2013; Lebeau, 2012). Passive air sampling 
may be conducted in a rural environment to evaluate environmental air quality (Jaward et al. 2005). 
In occupational settings, exposures to toxicants may be assessed through biomonitoring which 
measures the body burden of toxicants and their metabolites through the analysis of human fluids 
(e.g., blood) (Lebeau, (2012). 
 
2.4 Biomonitoring         
Biomonitoring is the process of determining the presence of chemicals in the human body 
as a result of an exposure. Once a chemical has been absorbed due to an exposure to food, air 
water, dust, etc., and depending on the pharmacokinetics of the chemical, it may be measured in 
various biological media. These commonly include the sampling of urine, blood, breast milk, 
tissue, etc. The chemicals being analyzed in biological media are often referred to as biological 
markers. Measurable concentrations of the parent chemical and its intermediate or conjugate 
allows for the prediction of a human health effect (Centers for Human Health Assessment, 2017). 
A measured chemical concentration can also be used to determine previous health effects based 
on current levels in the body (Centers for Human Health Assessment, 2017; Lebeau, 2012). Their 
concentrations can be used to identify early physiological changes. In addition, based on key 
metabolic characteristics of certain individuals, biological markers can be used to determine health 
effects, given a level of exposure. Although, the presence of a chemical in a biological sample 
does not automatically indicate a health effect (Ames et al., 1990a,b). 
 
In the process of biomonitoring, there are at least three factors that affect the detection of 
biological markers; one of which is half-life. Each chemical has a half-life, which is the time it 
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takes for a concentration of a chemical to decrease by half in the human body. If the chemical has 
a relatively brief half-life of one day, it is imperative to analyze the biological samples as quickly 
as possible. Thus, one must be aware of a chemical’s half-life, as it is a key consideration in 
biomonitoring results. Other factors that affect the detection of biological markers include the 
physical characteristics of the chemical and the detection limits of the instrument being used 
(Aylward et al., 2013; Centers for Human Health Assessment, 2017; Lebeau, 2012).  
 
As previously mentioned, there are various uses for biomonitoring. Biomonitoring is used 
to determine environmental (indoor or outdoor) and occupational exposures to toxicants. At the 
crux of biomonitoring is the need to understand if a population is at-risk after a chemical exposure. 
Thus, in the occupational setting for instance, biomonitoring is crucial if workers tend to work 
with chemicals at levels that are known to cause injurious health effects. Baseline levels of 
toxicants may be recorded for a group of workers. Over time, biological samples are taken from 
the workers on a routine basis. This allows us to determine whether concentrations of toxicants 
have increased significantly and may lead to a health effect (Lebeau, 2012).  
 
On a regional or national level, biomonitoring serves as an important tool to gauge the 
background levels of people among various American demographic categories. Public health 
researchers use this biomonitoring data to determine if the reported levels of toxicants are 
associated with various human health effects. An example of regional biomonitoring includes 
studies of large populations in the Center for the Health Assessment of Mothers and Children of 
Salinas (CHAMACOS) Study which is one of the longest running longitudinal birth cohort study 
of pediatric environmental exposures in a farmer community (Castorina et al., 2011; Eskenazi et 
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al., 2013). A similar study is the Health Outcomes and Measures of the Environment (HOME) 
Study in Cincinnati, Ohio from March 2003 to February 2006 which investigated the human health 
effects of low-level environmental toxicants (Vuong et al., 2015). On a much larger scale, 
scientists refer to the National Health and Nutrition Examination Survey (NHANES) to analyze 
biomonitoring data. NHANES biomonitoring data serves as the primary source of information for 
this dissertation research (Centers for Human Health Assessment, 2017). 
 
NHANES is administered by the Centers for Disease Control & Prevention’s National 
Center for Health Statistics. This biomonitoring program was started in the early 1960s and 
focused on specific populations and health topics (Centers for Human Health Assessment, 2017; 
Lebeau, 2012). In 1999, NHANES became a continuous biomonitoring program which changes 
focus based on several health and nutrition measurements that address emerging needs. A 
nationally representative sample of few thousand people are surveyed every year. Participants are 
from 15 counties throughout the country. NHANES data are released every two years. For 
biomonitoring specimens, participants are 6 years or older. Blood specimens are gathered from 
participants that are 12 years or older. It is important to note that the measured analytes cannot be 
used to estimate regional levels such as cities or states. They also cannot be used to generate 
estimates for populations with unusual exposures (Centers for Human Health Assessment, 2017).  
 
2.5 Brominated Flame Retardant Exposure      
2.5.1 Occupational Exposure        
Polybrominated Diphenyl Ethers are ubiquitous in our environment because they are used 
as flame retardants in a variety of materials. When considering the most at-risk populations as a 
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result of their occupations, we must seriously consider workers involved in the production, 
distribution, handling and disposing of materials that contain PBDEs. Naturally, e-waste workers 
and dismantlers fit this category very well (Darnerud et al., 2001). According to Watanabe & 
Sakai, in Japan, hazardous waste incinerators and final disposal sites are some key sources of 
brominated flame retardant effluents (Watanabe & Sakai, 2003). Among disposed wastes, 
televisions and computers may serve as significant sources of PBDEs. In comparison to 
transportation materials, electrical appliances, building materials and others, electronics contained 
over half of the relative amounts of flame retardants, as shown in Figure 1 (Darnerud et al., 2001; 
Watanabe & Sakai, 2003). As a result, their research has shown that workers at electronics-
dismantling facilities are among the most exposed individuals and appropriate measures should be 
taken to protect them along with those that handle other similar consumer waste products 
(Watanabe & Sakai, 2003). 
 
 
Figure 1. Relative amounts of flame retardants (including PBDEs) in various sectors (Darnerud 
et al., 2001). 
 
Sjodin et al. conducted a study of PBDE levels among full-time workers at a computer 
screen facility and clerks from an electronics-dismantling plant with hospital cleaners as the 
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control group. Sjodin et al. reported significantly higher concentrations of PBDEs among workers 
at the electronics-dismantling plant in comparison to hospital cleaners. Through this research, 
despite the relatively small sample size, results suggest that those who handle computer parts may 
have increased exposures to PBDEs (Sjodin et al., 1999). Also, BDE-47 was among the most 
prevalent BDE congeners among workers according to a study of 52 office workers in Boston, 
Massachusetts (Makey et al., 2016).   
 
Another potentially at-risk group of people due to the activities in which they partake 
include gymnasts. These athletes spend an inordinate amount of time with safety materials such as 
pit cubes and landing mats, which help to brace their fall during exercise. Because of their flame 
retardant content, materials used by gymnasts have been named as the primary culprits for the 
abnormally high concentrations of PBDEs found in these athletes. Research has also shown that 
apart from the materials, the facilities in which they train has been found to contain elevated levels 
of flame retardants in air and dust (Carignan et al., 2016). Carignan et al. have shown that these 
elevated levels of flame retardants corresponded with significantly higher concentrations of 
pentaBDEs in the blood serum of gymnasts. Concentrations were also significantly higher after 
practice in comparison to before practice, which suggests that elevated concentrations were likely 
due to contact with materials and dusts within the facility. Approximately 89% of foam samples 
from many training facilities contained flame retardants. Despite their interesting findings, this 
study was based on a relatively small sample of 53 participants; thus, leading to a relatively low 
statistical power (Carignan et al., 2016). However, it helps to identify another potentially at-risk 
group due to a specific type of activity or occupation. In general, further research should be 
conducted to determine the total PBDE body burden contribution of occupations in America. 
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2.5.2 Residential Exposure        
Unlike some regions of the world, the primary source of PBDE exposure in America is the 
indoor environment; especially, residential exposure. It is difficult to discuss residential exposure 
to PBDEs without considering the impact of California’s formerly strict flame retardant 
requirements. In 1975, Governor Jerry Brown signed the “Technical Bulletin 117” into law 
(Standen, 2013). This required all upholstered furniture to be injected with flame retardants like 
PBDEs. Since then, this law became a de facto national standard. Recently, California’s Technical 
Bulletin 117 has been revised. Beginning in 2014, on his most recent stint as California’s governor, 
Mr. Jerry Brown signed a revision to this law which no longer requires the injection of flame 
retardants into California’s furniture. However, prior to this revision, many studies investigated 
the impacts of Technical Bulletin 117 on PBDE levels among American residents; especially 
Californians (Standen, 2013). 
 
An increase of approximately one order of magnitude was reported for indoor air and dust 
concentrations of PBDEs in North America in comparison to Europe. The authors mention this 
disparity is likely due to a difference in fire standards between the two regions (Frederiksen et al., 
2009). According to Castorina et al., on average, PBDE blood levels were approximately 20 times 
higher in the US in comparison to Europe (Castorina et al., 2011). The total range of PBDE levels 
in Americans was from 4.2 to 1380 ng/g lipid. The pentaBDE mixture was traced in over 97% of 
samples. Researchers found that the total PBDE concentrations in Americans significantly 
increased with the length of time someone has resided in the United States, and in women living 
in Californian homes containing at least 3 pieces of stuffed furniture. Specifically, the possession 
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of 3 or more stuffed furniture was significantly associated with nearly a 27% increase in women’s 
blood concentrations of PBDEs (Castorina et al., 2011).  A study by Harley et al. also indicated 
that the strongest predictor of PBDE concentrations among pregnant women living in a low-
income mostly-Hispanic immigrant community in California, was residence time (Harley et al., 
2010). 
 
Zota et al. investigated the impacts of California’s flammability standards. Comparisons 
were made between PBDE levels in household dusts from Californian homes and those from seven 
other regions in the United States. A significantly higher household dust level of PBDEs was found 
in Californian homes compared to other regions in America. Investigators also reported 
approximately a two-fold increase in blood serum concentrations of PBDEs; that is, a least square 
geometric mean of 73.0 vs. 38.5 ng/g lipid (Zota et al., 2008).  
 
Frederiksen et al. indicated that although foodstuffs with a high fat content had relatively 
higher levels of PBDEs, diet alone cannot explain background levels of PBDEs among Americans. 
It was determined that the ingestion of indoor dusts contributed to the highest intake of BDE-209. 
Infants, often displaying crawling behaviors, tend to be exposed to a variety of chemicals. Toddlers 
were found to have ingested a significantly higher amount of PBDEs from indoor dusts in 
comparison to adults. Infants are also exposed to PBDEs via breast feeding. Overall, they have a 
higher body burden in comparison to adults (Frederiksen et al., 2009). 
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2.5.3 Dietary Exposure        
Although diet is not the primary source of PBDE exposure in the United States, it remains 
a significant source. In many regions of the world diet is the primary source of exposure. When 
discussing diet, the main attribute of PBDEs to consider is their affinity to fat. Due to this 
lipophilicity, research has shown that foods heavy in fat like poultry, meat, and fish (especially 
from top predators) contain significantly higher levels of PBDEs in comparison to fruits and 
vegetables. In general, average dietary PBDE levels follow this trend: vegetables ≤ 
dairy<meat<fish. The PBDE content of North American meat was generally higher in comparison 
to other regions of the world (Frederiksen et al., 2009). Similarly, in a Finnish study of dietary 
PBDE intake, Kiviranta et al. found that approximately 53% of PBDE intakes were from Fish. 
These results were comparable to dietary PBDE intake studies in Sweden and Canada (Kiviranta 
et al., 2004). 
 
Fromme et al. investigated various sources of PBDE exposure among 27 healthy females 
and 23 healthy males in Germany. Researchers found that dietary exposure was responsible for 
97% of the average intake and 95% of the high intake of total PBDE intake in this adult population. 
Their findings coincide with other studies that have shown that diet is a significant exposure source 
in many European countries (Fromme et al., 2009).  
 
Since Fish, especially top predators, are key dietary sources of PBDEs it is important to 
note that some fish and marine organisms contain what Teuten et al. have determined to be 
naturally produced PBDEs. The True’s Beaked Whale is one such organism. Studies of these 
animals have found methoxylated polybrominated diphenyl ethers (MeO-PBDEs) which are 
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structurally-similar to synthetic PBDEs. Through methoxylation processes the PBDEs become 
MeO-PBDEs. Molecular-level C-14 analysis was used to determine the source of the halogenated 
compounds (Teuten et al., 2005). For example, a change of C-14 value of +90 per mil shows that 
the source was natural. On the other hand, a value of -990 per mil for Bromkal 70-5DE (a 
commercial mixture of PBDEs) indicated that the source was industrial. Just like their 
nonmethoxylated counterparts, MeO-47 and 68 showed a high propensity for bioaccumulation. 
The most likely source of exposure of MeO-PBDEs for the whales is dietary (e.g., squid 
consumption).  Microorganisms also naturally produce these compounds and the authors suggest 
that this may be a detoxification mechanism. The natural production of these compounds has been 
occurring before any known environmental release of industrial PBDEs. In fact, cytochrome p450 
and other enzymes used in the metabolism of these compounds are believed to have existed for 
millions of years and probably arose originally as a response mechanism for naturally produced 
compounds in the environment (Teuten et al., 2005). 
 
2.6 Polybrominated Diphenyl Ether Health Effects       
2.6.1 Acute                 
Acute human health effects after PBDE exposure is poorly understood and currently being 
investigated. In general, most of the information related to acute health effects of PBDE exposure 
is from animal studies. Thus far, in animals, decaBDE mixtures have been shown to be relatively 
less toxic in comparison to lesser-brominated BDE congeners. In humans, decaBDEs are expected 
to have very little health effect. This is due to its much different toxicity in comparison to lesser-
brominated congeners (ATSDR, 2017).  
 
  22 
In animals, one of the most significant health endpoints has been PBDEs’ potential effect 
on thyroid hormones. For example, rats and mice who were fed food laced with moderate amounts 
of lesser-brominated congeners for short periods had predominantly thyroid-related effects. 
However, it should be noted that thyroid disruption due to, short-term, small-to-moderate amounts 
of PBDE exposure is thought to be species-dependent. As a result, this suggests that similar effects 
are less likely to occur in humans. In addition, testing of animal offspring has also shown 
behavioral effects due to acute PBDE exposure (ATSDR, 2017). Once again, these behavioral 
effects are believed to be a result of changes in the thyroid since it is a major determinant of nervous 
system development. No additional birth defects have been recorded in animals after acute 
exposure. Much research is needed to determine if acute PBDE exposure has any reproductive 
health effects. Next, animal testing data of acute exposure has shown that some BDE congeners 
may affect the immune system and cause skin irritation if the animal’s skin is lacerated (ATSDR, 
2017). Furthermore, Darnerud et al. conducted studies pertaining to the clinical signs of toxicity 
after acute exposure. After rats were exposed to high doses of PBDEs, investigators reported the 
following clinical signs: diarrhea, red staining around the eyes and nose, reduced activity, 
continuous chewing, piloerection and clonic persistent tremors of forelimbs (Darnerud et al., 
2001).  
 
In humans, the only available data concerning acute PBDE health effects are from studies 
of decaBDE. In one skin sensitization study, involving 200 volunteers (120 females and 80 males) 
exposed to two decaBDE batches of unknown purity, no evidence of skin sensitization was 
observed. These participants were treated with nine induction patches every two days. For every 
treatment day, the test substance remained in contact with the participants’ skin for 24 hours. 
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Neither of the two undisclosed decaBDE batches had an effect on skin sensitization. In another 
study, the skin sensitization of a decaBDE mixture (decaBDE: 77.4%; nonaBDE: 21.8%;  and, 
octaBDE: 0.8%) was assessed for 50 volunteers. A five percent suspension of decaBDE in 
petrolatum was spread over the participants’ skin three times per week for a period of three weeks. 
Investigators did not find any skin sensitization among the participants (ATSDR, 2017). Finally, 
a study of workers involved in the manufacture of polybrominated biphenyls and polybrominated 
diphenyl ethers was conducted to investigate the acute health effects of PBDEs, including 
decaBDE. These workers were reported to have a higher prevalence of primary hypothyroidism 
and substantial reductions in conducting velocities in sensory and motor neurons than normal, after 
being acutely exposed to PBDEs at the workplace.  However, no other dermatologic or neurologic 
changes were found (Darnerud et al., 2001). 
 
2.6.2 Chronic                
Similar to acute health effects, the chronic health effects of PBDEs are poorly understood 
and requires a significant amount of research. Most of the known chronic health effects of PBDEs 
are from animal studies. It is speculated that a long-term exposure to PBDEs has a higher chance 
of causing health effects in comparison to short-term low levels of exposure. This is partly due to 
the bioaccumulative property of PBDEs which occur over many years of exposure. Once again, in 
relation to chronic health effects, decaBDEs are expected to be generally less toxic than lesser-
brominated counterparts. Of major importance to possible chronic health effects is the potential to 
cause cancer. Currently, it is unknown whether PBDEs can cause cancer in humans (ATSDR, 
2017; USEPA, 2014). 
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Although, rats and mice that ingested PBDEs throughout their lives developed liver tumors. 
Overall, investigators have found a statistically significant increase in the incidence of carcinomas 
in the livers of male rats exposed to low and high doses, and of female rats exposed to high doses. 
Secondly, a significant increase in cases of hepatocellular adenoma or carcinoma was found in 
male mice after low dose exposure (National Toxicology Program, 2006). Next, a significantly 
increased incidence of follicular cell hyperplasia was found in male mice after being exposed to 
high and low doses of decaBDE. The latter is thought to be a precursor to thyroid tumors in mice. 
It is based on this relatively limited body of evidence that the EPA postulates that decaBDE may 
possibly be carcinogenic to humans (ATSDR, 2017; USEPA, 2014). On the other hand, the EPA 
describes lower-brominated congeners as not classifiable as human carcinogens (USEPA, 2014).  
 
In case-control epidemiologic cancer studies, pancreatic cancer was not significantly 
increased with increased levels of lipid lower-brominated PBDEs. Next, in a study of women from 
California, of which were 78 cases and 56 controls, no significant association was found between 
adipose tissue concentrations of lower-brominated PBDEs and breast cancer. Third, a study of 
Alaskan women found no clear association between BDE-47 and breast cancer. In addition, blood 
concentrations of lower-brominated PBDEs were not significantly associated with thyroid cancer 
among participants from a large multicenter clinical trial in the U.S., which included 104 cases 
and 208 controls. Furthermore, in a study of Swedish men and women with 19 cases and 27 
controls, BDE-47 exposure was not significantly associated with non-Hodgkin’s lymphoma. Thus, 
from the relatively brief amount of human studies of cancer risks in relation to lower-brominated 
PBDE exposures, results have consistently shown that humans are not at significant risks to various 
forms of cancer (ATSDR, 2017).  
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2.6.3 Toxicokinetics         
In general, toxicokinetic studies of PBDEs have indicated that the absorption, metabolism 
and elimination of polybrominated diphenyl ethers are all dependent upon the congener, species 
and gender. Also, animal studies have shown that pups have a higher body burden of PBDEs than 
adults. This is because while a significant amount of PBDEs are transferred from mothers to pups 
through breast feeding, the pups have a lesser capacity for PBDE elimination. Just as in animal 
studies, children have been shown to carry a higher body burden of PBDEs in comparison to their 
parents (Costa & Giordano, 2007). In humans, when comparing the amount of absorbed 
polybrominated diphenyl ethers, with polychlorinated dibenzodioxins, polychlorinated dibenzo 
furans and co-planar polychlorinated biphenyls from 1973 to 2000, human PBDE levels have 
increased significantly while these other toxicants have all significantly decreased. The three most 
common congeners in humans have been BDE-47, followed by BDE-153, then BDE-99 (Costa & 
Giordano, 2007).  
 
2.6.3.1 Absorption                
In general, lesser-brominated congeners are more likely to enter the human body through 
the lungs and stomach, and pass into the bloodstream than decaBDE. Also, during pregnancy, 
PBDEs have been shown to enter the bodies of unborn babies through the placenta. Oral absorption 
estimates are available for PBDEs and include the following. After forced administration of 
PBDEs in lipophilic vesicles, the most recent estimates, show a range of 70-75% for BDE-47, 
BDE-99, BDE-100, BDE-153, and BDE-154. An estimated range of 10-26% is expected for BDE-
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209 (deca-BDE). The mechanisms of oral absorption, including active transport and protein 
binding, have not been determined (ATSDR, 2017). 
 
To assess the bioavailability of PBDEs, studies of in vitro gastrointestinal models have 
been conducted. Yu et al. found that the most important factor impacting PBDE bioaccessibility 
was dietary fat; likely due to the lipophilicity of PBDEs. Further study of the bioaccessibility of 
lesser-brominated BDE congeners in flour, rice, meat, fish and vegetables yielded a range of 2.6 
to 41.3% in foodstuffs. Bioavailability of PBDEs in food increased as fat, and carbohydrate content 
increased. On the other hand, bioavailability of PBDEs in food decreased with increasing protein 
and fiber content (Yu et al., 2009).  
 
The bioavailability of PBDEs have also been investigated in dust; the largest source of 
PBDE exposure. Research by Lepom et al. found that the bioavailability of PBDEs found in 
ingested dust was approximately less than 50%. From this investigation, researchers also reported 
a bioavailability of 27 to 42% for lesser-brominated BDEs and approximately 10% for BDE-209 
(Lepom et al., 2010). Similar results were found by Abdallah et al. Once again, the bioavailability 
of BDE-209 (14%) was much lower than that for lesser-brominated BDE congeners (32 to 58%) 
(Abdallah et al., 2012). 
 
A few in vitro studies have been performed to investigate the diffusion potential of PBDEs 
across dermal barriers for rats, mice, and human. According to Staskal et al., female mice that were 
exposed to a dermal dose of 1 mg/kg 14C BDE-47 had a dermal absorption efficiency of 62% 
(Staskal et al., 2005). Roper et al. reported that mean absorption efficiencies for 14C BDE-47 was 
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14.58% in rat skin and 1.88% for human skin (Roper et al., 2006). Finally, Hughes et al. report a 
mean absorption efficiency range of just 0.07-0.34% from the 14C decaBDE dose applied to mouse 
skin in vitro (Hughes et al., 2001).  
 
2.6.3.2 Distribution                
As previously mentioned, research has shown that infants have a higher body burden of 
PBDEs than their parents. One of the main reasons for the latter is due to PBDE absorption via 
breastmilk. However, research has also demonstrated that PBDEs are also distributed to the 
developing fetus from pregnant mothers via cord serum samples of non-occupationally exposed 
mothers (Li et al., 2013). The majority of congeners found in maternal, cord sera and breast milk 
samples have been tetraBDEs and pentaBDEs. Although, mounting evidence has shown the 
presence of hexaBDEs, octaBDEs and decaBDEs in cord sera and mothers’ breast milk (ATSDR, 
2017).  
  
The distribution of PBDEs in animal and human tissues has also been investigated. In one 
study, animals that were exposed to 14C-labeled BDE-47, BDE-99, BDE-100, BDE-153, BDE-
154, and BDE-209 (decaBDE) has shown that lower-brominated BDEs are distributed differently 
than decaBDE. Specifically, investigators found that after absorption and an initial wide 
distribution, lower-brominated congeners tended to accumulate more in adipose tissue. On the 
other hand, decaBDE tended not to be distributed in adipose tissue. Instead, decaBDE appeared to 
prefer highly perfused tissues, such as renal tissue, which are human tissues that circulate bodily 
fluids (ATSDR, 2017).  
 
  28 
 
2.6.3.3 Metabolism                
The primary metabolic pathway of PBDEs in humans and animals is oxidative 
hydroxylation and follows the following series of steps. Polybrominated diphenyl ethers are 
metabolized with phase I and phase II enzymes, forming hydroxylated PBDEs. Through this 
metabolic pathway, monohydroxylated OH-PBDEs are formed. Hydroxylated PBDEs have been 
found in samples of human blood and breast milk. These have also been found in the feces of 
rodents that were exposed to 14C-labeled tetraBDEs, pentaBDEs, hexaBDEs and decaBDEs. The 
process of PBDE oxidative hydroxylation has been validated in studies of in vitro metabolic 
systems with primary hepatocytes or liver chromosomes in humans and rats (Cheng et al., 2008; 
Erratico et al., 2011; Erratico et al., 2012; Erratico et al., 2013). Other metabolic fate processes for 
PBDEs in mammals include the metabolic cleavage of the ether bond leading to a formation of 
brominated phenols and the debromination of lesser-brominated PBDEs (Cheng et al., 2008; 
Erratico et al., 2012; Erratico et al., 2013). Data from in vivo toxicokinetic studies of rodents 
exposed to PBDEs have been deemed adequate by the ATSDR to propose the likely involvement 
of cytochrome P450s in the formation of hydroxylated metabolites and hydroxylated debrominated 
metabolites. Furthermore, in vitro studies of human liver microsomes or hepatocytes and human 
recombinant CYP enzymes have shown that through hydroxylation and cleavage of the ether bond, 
CYP2B6-mediated metabolism of BDE-47, 99 and 100 generated several metabolites, as 
illustrated in Figures 2-4 respectively (Erratico et al., 2012; Erratico et al., 2013). Research of 
human liver microsomes or hepatocytes has not shown a production of hydroxylated metabolites 
of BDE-153 and BDE-209 (Lupton et al., 2009). Finally, it is interesting to note that there are 
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naturally occurring OH-BDEs and brominated phenols known to be produced by sponges and 
algae in marine environments (ATSDR, 2017). 
 
 
 
Figure 2. Structures and General Metabolic Scheme for Hydroxylated Metabolites of BDE-47 
Produced by Human Liver Microsomes (Erratico et al., 2013).  
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Figure 3. Structures and General Metabolic Scheme for Hydroxylated Metabolites of BDE-99 
Produced by Human Liver Microsomes (Erratico et al., 2012). 
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Figure 4. Structures and General Metabolic Scheme for Hydroxylated Metabolites of BDE-99 
Produced by Human Liver Microsomes (ATSDR, 2017). 
 
 
2.6.3.4 Elimination                
Just as in the case of absorption, the elimination of PBDEs depends on the chemical 
structure of the BDE congener. In general, these flame retardants and their metabolites are 
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eliminated from the body mainly through feces. A relatively very small amount is eliminated in 
urine. DecaBDEs and their lower-brominated counterparts are all known to concentrate in human 
breast milk. Thus, breastfeeding may serve as an additional source of elimination for nursing 
mothers (Hooper et al., 2007; Jakobsson et al., 2012; Thomsen et al., 2010). The two general 
classes of congeners also differ in their half-lives within the human body. The half-life for lower-
brominated BDE congeners is approximately 94 days. For decaBDEs, the approximate half-life is 
significantly less at 15 days. Thus, lower-brominated PBDEs have a much longer residence time 
in the body (ATSDR, 2017). 
 
2.6.4 Mechanisms of Toxicity        
Following exposure to PBDEs, the primary systems of concern in humans include the 
following: the liver, nervous, male reproductive, developing and mature endocrine systems. 
Although, the female reproductive, adult nervous system and the developing and mature immune 
systems are also of concern, the evidence that is available for these endpoints is incomplete. Many 
studies have been conducted to elucidate the likely mechanisms of toxicity for PBDEs. General 
mechanisms of toxicity, such as Aryl hydrocarbon receptor (AhR)-mediated effects and hepatic 
enzyme induction, and target-specific mechanisms have been investigated. Most mechanistic 
studies, for specific targets, have been focused on neurological effects and endocrine disruption. 
PBDEs share similar toxicological properties as PCBs likely due to their two-dimensional 
structural similarities. However, PBDEs are more coplanar in nature due to the ether bridge. This 
reduces the AhR binding affinity when compared to similar compounds. As a result, PBDEs are 
less sensitive to the influence of ortho substitutions that inhibit the AhR binding capability of PCBs 
(ATSDR, 2017; ATSDR, 2002). These attributes have implications on the nondioxin-like and 
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dioxin-like effects of PBDEs, which are mediated by the AhR pathway. Studies of the structure-
activity of PBDEs have demonstrated that although some BDE congeners are able to bind to AhR, 
the binding affinities and induction of AhR-mediated responses are extremely weak or 
insignificant; especially for commercial PBDE mixtures (ATSDR, 2017). Finally, Dingemans et 
al. have reported that the toxicity of PBDEs should be investigated in conjunction with structurally 
similar compounds such as nondioxin-like polychlorinated biphenyls because there is evidence 
showing an additive effect when these two types of compounds are combined (Dingemans et al., 
2016). Meng et al. also reported synergistic effects between polybrominated diphenyl ethers, 
polychlorinated biphenyls and organochlorine pesticides in a study of the association between 
asthma and persistent organic pollutants among children in Shanghai, China (Meng et al., 2016). 
 
2.6.5 Toxicity Assessment         
The assessment of polybrominated diphenyl ethers will be limited to select outcomes. This 
assessment concerns the most important public health risks, in addition to obesity; the primary 
health outcome concerning this dissertation research. Moreover, epidemiological studies will be 
presented, if available.  
 
2.6.5.1 Developmental Effects                      
First, the neurodevelopment system is a target of concern in children for all PBDEs. 
According to various human studies, results suggest that PBDEs influence the neurodevelopment 
of children. In one cohort study, investigators found associations between maternal serum PBDE 
concentrations and decreased IQ, hyperactivity at age 5 and executive functions (mental control 
and self-regulation) deficits in those children from 5 to 8 years old (Braun et al., 2014; Chen et al., 
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2014; Donauer et al., 2015; Vuong et al., 2016). Other studies have reported a correlation between 
cord serum PBDE concentrations in breast milk and adaptive behavior deficits in infants, mental 
and physical developmental deficits in toddlers, social development and language deficits in 
children (24 months old), increased impulsivity in toddlers, and attention deficit hyperactivity 
disorder at age 4. Secondly, despite the inconsistency of developmental endocrine system effect 
research, epidemiological data suggest that PBDEs can interact with the homeostasis of thyroid 
hormones in infants and children. Human research showed inconsistencies in the investigation of 
infant serum or cord blood thyroxine levels and PBDE developmental exposure. Results have also 
been inconsistent when researchers investigated infant serum or cord blood triiodothyronine levels 
and thyroid stimulating hormone in association with PBDE developmental exposure. In numerous 
studies of animals, results have shown a reduction in serum triiodothyronine and thyroxine levels 
in pups after receiving doses of pentaBDE or tetraBDE as low as 452 mg/kg/day in mice and 0.3 
mg/kg/day in rats throughout gestation and lactation. Third, sufficient animal and limited human 
data has shown that oral exposure to PBDEs during development may potentially affect the male 
reproductive system (ATSDR, 2017). One study found, no relationships between maternal PBDE 
levels and hypospadias in boys, adipose tissue concentrations of PBDEs in children and 
cryptorchidism, or any measures of sexual maturation in girls (Carmichael et al., 2010). Yet, an 
American longitudinal cohort study found a significant association between blood levels of PBDEs 
for 6 to 8-year-old girls and delayed onset of puberty. However, more research is needed to 
determine if PBDE levels in infants and children can cause altered reproductive effects in 
adulthood. Last, limited animal and human data have shown that exposure to PBDEs may be able 
to cause low birth weight among other endpoints of human physical development. However, such 
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conclusions are relatively inconsistent (Costa & Giordano, 2007; Kuriyama et al., 2005; Lilienthal 
et al., 2006; Toms et al., 2009a,b; Viberg et al., 2003). 
 
2.6.5.2 Endocrine Effects                       
Several epidemiologic studies have investigated possible endocrine system effects of 
PBDE exposure. First, many human studies have shown that PBDEs can disturb the endocrine 
system and hormone levels. In one study conducted by Hooper et al., 4 production workers out of 
a sample of 35 who worked at a decaBDE manufacturing plant presented with hypothyroidism 
(Hooper & McDonald, 2000). However, specific findings in human studies have been very 
inconsistent. Some studies have reported positive associations between thyroxine and PBDEs 
while others have reported negative or no associations (ATSDR, 2017). Similar inconsistencies 
exist for research concerning the association of thyroid stimulating hormone or triiodothyronine 
with PBDE concentration. Although, there is sufficient data supporting the ability for PBDEs to 
interact with the homeostasis of the thyroid hormone. Overall, current data from human and animal 
studies suggests that the thyroid is likely a target of concern for humans (Costa & Giordano, 2007; 
Hamers et al., 2006; Hooper & McDonald, 2000; Kim et al., 2012; Kovarich et al., 2011; Li  et al., 
2013; Lilienthal et al., 2006; Norrgran et al., 2017). 
 
Finally, the pancreatic effects of PBDEs have been studied in humans and animals. 
Epidemiologic studies have been inconclusive. However, animal studies have shown that the 
pancreas may be a target of concern after an oral dose of PBDE is provided. For example, a study 
of male rats that were exposed to approximately 20 mg/kg/day to PBDEs in food for 70 days 
showed a reduction in serum glucose levels. However, it should be noted that the study did not 
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report the lowest dose at which point glucose levels were significantly lower in male rats. Another 
study, investigated insulin regulation and pancreatic morphology in male rats after being exposed 
to 0, 0.05, 1, or 20 mg/kg/day of decaBDE every day for a period of 8 weeks. Investigators reported 
that the rats exposed to 1 and 20 mg/kg/day had a significant 50-60% decrease of serum insulin. 
In addition, rats that were exposed to 0.05, 1 and 20 mg/kg/day had a significant increase of glucose 
levels by 12, 18, and 21%, respectively (ATSDR, 2017; Ernest et al., 2012). 
 
2.6.5.3 Hepatic Effects               
Currently, the potential human hepatotoxic effects of PBDEs is based primarily on animal 
data. There are no known animal studies of liver toxicity resulting from chronic lower-brominated 
PBDE exposure. Also, for decaBDEs, hepatotoxic effect research have been relatively 
inconsistent. Based on animal studies, acute exposure to lower-brominated BDE exposure is 
potentially toxic to the human liver. Furthermore, pups appear to be more susceptible to liver 
damage after decaBDE exposure, when compared to adult animals. Research has shown an 
increase in liver weights and diffuse liver cell hypertrophy with increased cytoplasmic eosinophilia 
in female rat pups that were exposed to ≥2 mg/kg/day and male rat pups exposed to 146 mg/kg/day 
of decaBDE. Research has also shown that fatty degeneration and elevated liver enzymes can occur 
in male rats after receiving a decaBDE dose that is ≥300 mg/kg/day (ATSDR, 2017). 
 
2.6.5.4 Body Mass Index                         
A primary focus of this dissertation research is an investigation of the potential association 
of PBDEs and obesity. Studies in this area of research has been relatively limited and inconclusive. 
However, the following are some epidemiologic findings concerning the association of body mass 
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index (BMI) with PBDE levels. The Centers for Disease Control & Prevention defines obesity as 
having a BMI that is greater than 30. BMI is a calculation of an individual’s weight in kilograms 
divided by the square of height in centimeters. In general, research shows that there is a moderate 
correlation between BMI and body fat (Centers for Disease Control & Prevention [CDC], 2015). 
This is important to remember due to the lipophilicity of PBDEs and their propensity to accumulate 
in the human body (Hooper & McDonald, 2000). First, in a study of Taiwanese mothers, 
investigators reported that children had low birth weight and height, and a decrease in Quetelet’s 
BMI, after a daily intake of 20.6 ng/kg/day via breastmilk (Costa & Giordano, 2007). This dose is 
lower than the average levels of PBDEs found in American human breast milk (approximately 306 
ng/kg/day) but higher than levels reported in the general Taiwan population in 2001 (Costa & 
Giordano, 2007). Other studies have reported no associations between PBDE exposure and the 
latter physical health endpoints in children. Next, a follow-up study of the Center for the Health 
Assessment of Mothers and Children of Salinas cohort was conducted to investigate the association 
between blood levels of BDE-47, 99, 100, and 153 with measures of obesity like obesity and 
overweight status, BMI and waist circumference. This investigation was conducted for 224 parents 
and 216 children from 2-7 years old. Investigators found no association between PBDE levels and 
measures of obesity. Although, once investigators adjusted for gender, significant effect 
modification was observed. Thus, investigators conducted the analyses separately, for each gender, 
and found a significant positive relationship between BMI z-score in 3.5-year-old boys and a 10-
fold rise in PBDE levels. This suggests that PBDEs have potential obesogenic effects for in-utero 
exposure in male boys (ATSDR, 2017). On the other hand, a significant negative association was 
observed in 3.5-year-old girls. Interestingly, Vuong et al. have reported no significant association 
between PBDE levels in maternal blood, during the 16th week of pregnancy (geometric mean of 
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39.1 ng/g lipid), and weight or height of children from 1 to 8 years old. However, Vuong and 
colleagues found a negative association between BDE-153 and body mass index for children who 
were 2 to 8 years old. A lower percent of body fat was also found for 8-year-old children (Vuong 
et al., 2016). Finally, Agay-Shay et al. also found no significant associations between BMI z-scores 
or risk of being overweight in children and maternal PBDE colostrum levels. It should be noted 
that Agay-Shay et al. did not separate their analyses by sex as was done in the abovementioned 
Salinas cohort study (Agay-Shay et al., 2015). 
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Chapter 3 
Methods 
3.1 Data Source 
The data analyzed for this research was generated from the 2003-2004 National Health and 
Nutritional Survey (NHANES). NHANES is a major data collection program of the National 
Center for Health Statistics (NCHS), which is a part of the Centers for Disease Control and 
Prevention (CDC). The primary goal of NCHS is to generate vital and health statistics for the 
country. Thus, the primary function of NHANES is to evaluate the health and nutritional status of 
American children and adults. In order to generate statistical data on the amount, type, and 
distribution of illnesses and disabilities within the United States, the National Health Monitoring 
Act of 1956 was created (CDC, 2012). 
 
The NHANES program was officially operational in the early 1960s. Since then, it has 
conducted various surveys focused on different demographic groups and health topics. Prior to 
1999, NHANES had been conducted periodically for periods of 2-4 years. However, there would 
be periods of 1-5 years where health data were not being collected. Since 1999, the NHANES 
program, now known as Continuous NHANES, has collected health and nutritional data on a 
yearly basis to address emerging health concerns (CDC, 2012; Donauer et al., 2015).  
 
The NHANES program surveys a representative sample of the American population every 
year, amounting to approximately 5,000 people. These survey participants inhabit 15 counties 
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throughout the country, which NHANES visit on a yearly basis. NHANES intentionally 
oversamples minority populations (e.g., African Americans, and Hispanics) and the elderly (60 
years or older) to produce reliable statistics. As it relates to the elderly, NCHS is currently 
attempting to increase the knowledge concerning their health status. NHANES is a primary vehicle 
for this target. While all participants visit the physician, in general, the older the person the more 
extensive the examination tends to be. As it relates to minorities, oversampling is conducted 
because minority groups tend to have drastically different health status and characteristics in 
comparison to non-minorities (CDC, 2012; Donauer et al., 2015). 
 
The current annual NHANES randomly selects approximately 7,000 American residents 
who have an opportunity to participate in the survey. It is also important to note that their 
participation is voluntary and confidential. Participants that are selected for the survey receive a 
standardized physical examination along with a personal interview. The health interviews are 
conducted in the homes of survey participants. The health examinations, on the other hand, are 
conducted in fully-equipped and specially-designed mobile examination centers (MECs) that 
travel across the nation during the survey period. These MECs are staffed with dietary and health 
interviewers, physicians, medical and health technicians. Many of the staff members are 
multilingual; especially in English and Spanish. In addition, the MECs uses a state-of-the-art 
computers system using high-end servers which efficiently processes the NHANES data while 
eliminating the use of manual coding or paper forms of data collection and reducing the potential 
for coding errors. When necessary, participants are provided vehicle transportation to and from the 
MECs. Surveyed individuals are provided a detailed summary of medical findings and are 
compensated for their participation (CDC, 2012; Donauer et al., 2015).  
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The collected data is published publically on the NHANES website and include the 
following subsets: Demographics, Dietary, Examination, Laboratory, Questionnaire, and Limited 
Access (NHANES, 2005a,b; NHANES, 2007; NHANES, 2008a,b). Demographics, Examination 
and Laboratory subsets were used for this dissertation research. From the Demographics subset, 
the Demographic Variables & Sample Weights XPT extension file was downloaded to include 
age, gender and ethnicity in the analytical models. From the Examination subset, the Body 
Measures XPT extension file was downloaded to include height (cm), weight (kg) and body mass 
index (BMI). From the Laboratory subset, the Brominated Flame Retardants XPT extension file 
was downloaded to include all the polybrominated diphenyl ether concentrations found in the 
blood serum of study participants. Also from the laboratory subset, the Cholesterol – Low Density 
Lipoprotein (LDL) & Triglycerides XPT was downloaded to include the LDL cholesterol and 
triglycerides. This process was repeated for comparative analyses of phthalates using the 
Phthalates – Urine XPT file, and Dioxin-Like PCBs using the Dioxins, Furans, & Coplanar PCBs 
XPT file. Each of the XPT extension files are attached with a word document which provide a 
description of the measured variable, limit of detection when necessary, sample requirements, 
sampling protocols and procedures, and other important information pertaining to the data.  
 
3.2 Sampling 
3.2.1 PBDE Sampling 
Participants that were eligible for this research were 12 years or older; age-capped at 85 
years old. This includes a total of 2337 individuals. For confidentiality and for cross-analyses of 
data, every individual was assigned a unique survey participant identifier (SEQN). Their PBDE 
  42 
concentrations were determined from an extraction of blood serum and/or plasma from each 
participant. These specimens were collected in vials and stored under the appropriate frozen 
temperature of -20 °C as elicited in the NHANES Laboratory/Medical Technologists Procedures 
Manual (LPM). Once specimens were collected, they were processed and shipped to the Division 
of Environmental Health Laboratory Sciences, National Center for Environmental Health, Centers 
for Disease Control and Prevention for examination (CDC, 2012; NHANES, 2007). 
 
The concentration of PBDEs are measured after sample cleanup and by using solid-phase 
extraction. First, samples are pretreated using a Gilson 215 liquid handler. This process involves 
the automated addition of internal standards, formic acid (denaturant) and water (diluent) and 
mixing in-between each addition by rotation. The use of formic acid allows for the extraction of 
the PBDEs from the samples. Next, during the extraction step, the analytes of interest of transferred 
from an aqueous medium to an organic solvent. Then, samples are cleaned up by removing co-
extracted lipids through elution of the extract, using 8 mL of hexane, through a column of silica 
(0.1g) and 1 g of silica/sulfuric acid (33% by weight). PBDE samples are cleaned and extracted 
using an automated solid phase extraction workstation (Rapid Trace®, Caliper Life Sciences). In 
addition, samples are evaporated by controlling vacuum, temperature and vortex action using 
RapidVap® (LabConco) and transferred into gas chromatography vials for analysis (NHANES, 
2007). 
 
Isotope dilution gas chromatography high-resolution mass spectrometry (GC/IDHRMS) is 
used to determine the final concentration of PBDE congeners. GC/IDHRMS allows for the 
reduction or elimination of many interferences typically associated with low-resolution 
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measurement of organohalogen compounds. Serum concentrations are reported in a lipid weight 
basis (ng/g lipid) which is preferable due to PBDEs affinity for lipids and, thus, are distributed 
within the body according to the distribution of the tissues lipid content (NHANES, 2007).  
 
3.2.2 DL-PCB Sampling 
Participants that were eligible for this research were 12 years or older; age-capped at 85 
years old. This includes a total of 1723 individuals. For confidentiality and for cross-analyses of 
data, every individual was assigned a unique survey participant identifier (SEQN). Their dl-PCB 
concentration was determined from an extraction of blood serum and/or plasma from each 
participant. These specimens were collected in vials and stored under the appropriate frozen 
temperature of -20 °C as elicited in the NHANES Laboratory/Medical Technologists Procedures 
Manual (LPM). Once specimens were collected, they were processed and shipped to the Division 
of Environmental Health Laboratory Sciences, National Center for Environmental Health, Centers 
for Disease Control and Prevention for examination (CDC, 2012; NHANES, 2008a). 
 
Nine dL-PCBs were measured in serum using high resolution gas chromatography/isotope-
dilution high-resolution mass spectroscopy (HRGC/ID-HRMS) and include the following: PCB 
105, PCB 118, PCB 156, PCB 157, PCB 167, PCB 189, PCB 126, PCB 81, PCB 169. 5 to 10 mL 
serum specimens to be analyzed for dl-PCBs were spiked with 13C-labeled (13C12) internal 
standards. Then, the analytes of interest were isolated in hexane using the C18 solid phase 
extraction which was followed by a Power-Prep/6 (Fluid Management Systems) automated 
cleanup and enrichment procedure using acidic, basic, and neutral multilayered silica gel and 
alumina columns coupled to an AX-21 carbon column. From carbon to toluene, Dl-PCBs are 
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isolated in the reverse direction. After sample cleanup, a Turbovap II (Caliper Life Sciences) was 
used to evaporate excess solvent to 350 µL. The remaining solvent was transferred to silanized 
auto sampling vials which contained 1 µL of dodecane “keeper” and was allowed to go to 
“dryness”. Each vial was reconstituted with 5 µL 13C12-labeled external standard before 
quantification. Then, sample extracts were analyzed for dl-PCBs by HRGC/ID-HRMS. Using a 
GC Pal (Leap Technology) auto sampler, 2µL were injected into an Agilent Technologies 6890 
Gas Chromatograph operated in the splitless injection mode with a flow of 1 mL/minute helium 
through a DB-5ms capillary column (30 m × 0.25 mm × 0.25 µm film thickness) where analytes 
are separated prior to entering a Thermo Finnigan MAT95 XP (5 kV) magnetic sector mass 
spectrometer operated in EI mode at 40 eV, using selected ion monitoring (SIM) at 10,000 
resolving power (10% valley) (NHANES, 2008a). 
 
In order to calibrate the mass spectrometer response factor v. concentration, calibration 
standards containing known concentrations of each native (12C12) compound and its 
corresponding 13C12 internal standard were used. Through interpolation from individual linear 
calibration curves the concentration of each analyte was derived and adjusted for sample weight. 
A variety of established criteria to evaluate the validity of all mass spectrometry data including: 
signal-to-noise ratio ≥ 3 for the smallest native ion mass, relative retention time ratio of native to 
isotopically labeled analyte within 3 parts per thousand compared to a standard, chromatographic 
isomer specificity index with 95% limits, instrument resolving power ≥ 10,000, response ratios of 
the two 12C12 and 13C12 ions within ± 20 % of their theoretical values and analyte recovery≥10 % 
and ≤ 120%. The method detection limit was calculated by correcting for sample weight and 
recovery, for each analyte. A summation method was used to estimate total lipid content of each 
  45 
specimen from its total cholesterol and triglycerides values. Serum concentrations are reported in 
ng/g lipids (NHANES, 2008a). 
 
3.2.3 Phthalate Sampling 
In order to compare results with those of PBDE analyses, participants from 6 to 11 years 
old were removed from the data set. Participants that were eligible for this research were 12 years 
or older; age-capped at 85 years old. This includes a total of 2263 individuals. For confidentiality 
and for cross-analyses of data, every individual was assigned a unique survey participant identifier 
(SEQN). Phthalate concentration was determined from urine samples from each participant. These 
specimens were collected in vials and stored under the appropriate frozen temperature of -20 °C 
as elicited in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM). Once 
specimens were collected, they were processed and shipped to the Division of Environmental 
Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease 
Control and Prevention for examination (CDC, 2012; NHANES, 2008b). 
 
High performance liquid chromatography-electrospray ionization-tandem mass 
spectrometry (HPLC-ESI-MS/MS) was used for the quantitative detection of the following 
phthalate metabolites in urine: mono(2-ethyl-5-carboxypentyl) phthalate (mECPP), mono(2-ethyl-
5-hydroxyhexyl) phthalate (mEHHP), mono(2-ethyl-5-oxohexyl) phthalate (mEOHP), 
monoisononyl phthalate (mNP), monobenzyl phthalate (mBzP), monooctyl phthalate (mOP), 
mono (2-ethylhexyl) phthalate (mEHP), monocyclohexyl phthalate (mCHP), mono (3-
carboxypropyl) phthalate (mCPP), mono-isobutyl phthalate (miBP), monobutyl phthalate (mBP), 
monoethyl phthalate (mEP) and monomethyl phthalate (mMP). Urinary samples were processed 
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using enzymatic deconjugation of the glucuronidated phthalate monoesters. This was followed by 
on-line solid phase extraction along with reversed phase HPLC-ESI-MS/MS. The incorporation of 
isotopically-labeled internal standards for each of the phthalate metabolites allowed the 
improvement of assay precision. Also, 4-methyl umbelliferone glucuronide was used to track 
deconjugation efficiency. Urinary concentrations are reported in ng/mL (NHANES, 2008b). 
 
3.3 Data Analysis 
Demographics, Examination and Laboratory XPT extension files were downloaded from 
the 2003-2004 NHANES. These laboratory subsets were uploaded and merged into SAS statistical 
software (Version 9.4) for preliminary analyses. Preliminary analyses included generating 
frequency distributions for all demographic groups and analytes (e.g., PBDEs, dl-PCBs, 
Phthalates). For PBDEs, analyses were performed on a sum of 10 congeners and two of the most 
prevalent congeners, BDE-47 and BDE-99, representing 75% of PBDEs in commercial mixtures 
(NHANES, 2007.). For dl-PCBs, analyses were performed on 9 congeners (NHANES, 2008a). 
For Phthalates, analyses were performed on 13 phthalate metabolites (NHANES, 2008b). 
Descriptive statistics such as the mean, minimum, maximum, standard deviation and standard error 
were calculated for analyte concentrations given age, gender, and ethnicity. Microsoft Excel was 
also used to generate graphs and tables for data visualization and supplementary analysis.   
 
During preliminary analyses of the concentration of analytes, it was determined that 562 
observations did not have a recorded concentration for dl-PCBs; and 434 were missing for 
phthalates (NHANES, 2008b). These observations were removed from the analyses to reduce bias. 
In addition, 297 observations had concentrations which were below the limit of detection (LOD) 
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for PBDEs. The LOD of every BDE congener was identified from the NHANES Lab Manual for 
PBDEs. Following industrial convention, the missing values were replaced by LOD/Square root 
(2) (NHANES, 2007). There were other instances where the data of interest was missing. 
Specifically, some individual data was missing for height in kg, weight in cm, BMI, triglycerides, 
and LDL cholesterol. In these cases, the missing data were omitted to reduce the bias or 
misinterpretation of analytical results.  
 
To investigate the validity of the research hypotheses, the following analyses were 
performed. Two major statistical procedures were utilized including analysis of variance 
(ANOVA) and logistic regression, when appropriate. First, ANOVA was calculated for any 
analysis that included dichotomous (or categorical) variables such as gender, age group or 
ethnicity. ANOVA was used to determine whether the average concentrations of analytes were 
significantly different among genders, age groups, ethnicities, and genders and ethnicities. A 
significance level of 0.05 (95% confidence level) was used for all ANOVA analyses. In other 
words, a resulting p-value less than 0.05 indicated a significant result.  
 
In addition, a logistic regression was conducted for BMI, given quartiles of analyte 
concentrations. Quartiles of analyte concentration were generated for statistical significance. It 
should also be noted that the CDC generates BMI values for adults who are 20 years or older. 
Thus, the data analysis of BMIs excluded participants who were under the age of 20. Based upon 
guidelines set forth by the CDC, participants were categorized according to their BMI. 
Specifically, participants were marked as underweight (BMI<18.5), normal or healthy weight 
(BMI=18.5-24.9), overweight (BMI=25.0-29.9), or obese (BMI≥30) (CDC, 2015). The logistic 
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regression analyses were used to calculate odds ratios (OR) which determined whether higher 
concentrations of a given analyte led to a higher odd of being overweight or obese. These analyses 
incorporated age (20 years or older), gender, ethnicity, LDL cholesterol, triglycerides and analytes 
separated into quartiles. If the OR values are equal to 1, this signifies that there is no difference 
between comparative groups in relation to an outcome of interest. If OR is above or less than 1 
than one of the two measure groups has a greater or lesser odd, respectively, of achieving an 
outcome in question. The further away from 1 the OR, the more drastic the difference between the 
two comparative groups (e.g., males v. females). To account for precision of OR measurements, 
95% Wald confidence limits are assigned for each calculation of OR point estimates. A point 
estimate outside of that confidence interval is deemed significant. 
 
Lastly, analyte concentrations among demographic categories were specifically compared 
using a paired t-test in Microsoft Excel. For each analysis a 95% confidence interval was utilized, 
where a calculated p-value less than 0.05 indicated a significant result. Correlation coefficients 
were used to present the strength of association among analyte concentrations. In addition, 
correlation of determinations were generated to measure the percent of variation that could be 
explained by the regression equation. 
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Chapter 4 
Results 
Results are ordered by analyte(s); that is, BDE-47, BDE-99, sum of PBDEs, dl-PCBs, 
followed by phthalates. Analysis for each analyte(s) was conducted to determine the following:  
• Frequency distribution of analytes, demographic categories and demographic 
categories per quartile. 
• Average concentration of analytes for all individuals in the sample and per 
demographic category.  
• Comparison of means for all demographic categories using ANOVA. 
• Calculation of odds of being overweight and obese in association with analyte 
concentration compared to other factors, using logistic regression.  
• Comparison of results using paired t-test. 
• Summary of results. 
 
4.1 Overall Detection Frequency   
 Analytes were detected in at least 85% of samples. Samples detected include values that 
were below the limit of detection, which were subsequently treated using LOD/Square root (2). 
These values could not be separated from the graph since they were not enumerated for dl-PCBs. 
The CDC automatically used the LOD/Square root (2) treatment for such analytes. Also, it 
should be noted that for the sum of all PBDEs, missing values from individual congeners were 
  50 
automatically omitted in SAS and did not affect the final concentrations calculated for 
participants.   
   
 
 
Figure 5. Number of samples detected. 
   
 
Table 2. Detections among individuals in the dataset. 
 
  BDE-47 BDE-99 All PBDEs* All dl-PCBs All 
Phthalates 
Samples Detected 2016 1985 2337 2285 2697 
 Missing 321 352 0 562 434 
 Percent 
Detected 
86.26% 84.94% 100.00% 80.26% 86.14% 
*Note: Although the sum of PBDEs contains some missing values, when calculating the sum 
of concentrations SAS automatically ignores missing values. 
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4.2 Polybrominated Diphenyl Ethers                
4.2.1 BDE-47                    
4.2.1.1 Frequency Distributions  
 
 
Figure 6. Frequency distribution of BDE-47 per quartile range. 
 
 
Table 3. Frequency distribution table of BDE-47 per quartile range. 
 
BDE-47 (Quartiles)   
Concentration Range Frequency Percent Min Max 
Q1 (0-6.8) 584 24.99% 0.004384062 2350 
Q2 (6.8-17.5) 584 24.99%   
Q3 (17.5-40.1) 584 24.99%   
Q4 (40.1-2350) 585 25.03%   
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Table 4. Frequency distribution table of age ranges cross-referenced with BDE-47 quartiles. 
RIDAGEYR refers to age in years from the 2003-2004 NHANES Demographic dataset and 
LBXBR3LA refers to BDE-47 from the 2003-2004 NHANES Brominated Flame Retardants 
dataset.  
 
 
  
            
Table 5. Frequency distribution table of gender cross-referenced with BDE-47 quartiles. 
RIAGENDR refers to gender from the 2003-2004 NHANES Demographic dataset and 
LBXBR3LA refers to BDE-47 from the 2003-2004 NHANES Brominated Flame Retardants 
dataset. 
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Table 6. Frequency distribution table of ethnicity cross-referenced with BDE-47 quartiles. 
RIDRETH1 refers to CDC-defined ethnicity from the 2003-2004 NHANES Demographic 
dataset and LBXBR3LA refers to BDE-47 from the 2003-2004 NHANES Brominated Flame 
Retardants dataset. 
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4.2.1.2 Comparative Statistics  
 
 
 
Figure 7. Comparison of average BDE-47 concentrations among age groups, in years. 
Difference in mean BDE-47 concentrations between age groups were insignificant; p-value 
>0.05. 
 
 
Table 7. Comparison of average BDE-47 concentrations among age groups, in years. 
 
Age Group, in years 12 to 18 19 to 30 31 to 50 51 to 84 85 and Above 
Concentrations, in ng/g lipids 40.068 43.083 40.411 44.275 56.318 
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Figure 8. Comparison of average BDE-47 concentrations among genders. Difference in mean 
BDE-47 concentrations between genders were significant; p-value <0.05. 
 
 
Table 8. Comparison of average BDE-47 concentrations among genders. 
 
Gender Male Female 
Concentrations, in ng/g 
lipids 
47.524 37.476 
 
 
 
 
Figure 9. Comparison of average BDE-47 concentrations among ethnic groups. Difference in 
mean BDE-47 concentrations between ethnicities were insignificant; p-value >0.05. 
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Table 9. Comparison of average BDE-47 concentrations among ethnic groups. 
 
Ethnicity Mexican 
American 
Other 
Hispanic 
Non-
Hispanic 
White 
Non-
Hispanic 
Black 
Other Race - 
Including Multi-
Racial 
Concentrations, 
in ng/g lipids 
39.819 31.341 42.463 46.681 37.145 
 
 
 
 
Figure 10. Comparison of average BDE-47 concentrations among gender and ethnicities. 
Difference in average BDE-47 concentrations is insignificant, given genders & ethnicities; p-
value >0.05. 
 
 
Table 10. Comparison of average BDE-47 concentrations among gender and ethnicities. 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Mexican_Male 42.751 
OtherHispanic_Male 37.614 
White_Male 46.760 
Black_Male 55.072 
OtherRace/Multiracial_Male 43.671 
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Table 10. (continued). 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
OtherHispanic_Female 25.711 
White_Female 38.504 
Black_Female 38.545 
OtherRace/Multiracial_Female 32.485 
 
 
 
 
Figure 11. Comparison of average BDE-47 concentrations among males and ethnicities. 
Difference in average BDE-47 concentrations is insignificant, given males & ethnicities; p-value 
>0.05. 
 
 
Table 11. Comparison of average BDE-47 concentrations among males and ethnicities. 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Mexican_Male 42.751 
OtherHispanic_Male 37.614 
White_Male 46.760 
Black_Male 55.072 
OtherRace/Multiracial_Male 43.671 
42.751 37.614 46.760
55.072 43.671
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Figure 12. Comparison of average BDE-47 concentrations among females and ethnicities. 
Difference in average BDE-47 concentrations is insignificant, given females & ethnicities; p-
value >0.05. 
 
 
Table 12. Comparison of average BDE-47 concentrations among females and ethnicities. 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Mexican_Female 37.030 
OtherHispanic_Female 25.711 
White_Female 38.504 
Black_Female 38.545 
OtherRace/Multiracial_Female 32.485 
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4.2.1.3 Logistic Regression Statistics 
 
 
 
Figure 13. Odds of being overweight in relation to blood concentration of BDE-47. From a 
logistic regression model containing Gender, Age, Ethnicity and Quartiles as exposure variables 
and Overweight BMI as the outcome, Ethnicity is the only significant exposure variable which 
increases the odds of being overweight. Most interestingly is the 1.841 odds ratio produced for 
Other Hispanic (non-Mexican) Vs. Mexican categories. 
 
 
Table 13. Odds of being overweight in relation to blood concentration of BDE-47. 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Female v. Male 0.717 0.517 0.995 
Age in Years 1.009 1.000 1.017 
High v. Low Triglycerides  1.292 0.852 1.959 
High v. Low LDL 1.288 0.784 2.116 
OtherRace & Multiracial v. Mexican 
American 
0.627 0.249 1.576 
NonHispanic Black v.  Mexican American 0.782 0.465 1.317 
NonHispanic White v.  Mexican American 0.980 0.644 1.491 
Other Hispanic v.  Mexican American 1.841 0.703 4.824 
0.717 1.009 1.292 1.288 0.627 0.782 0.980 1.841 1.465 1.007 1.072
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Table 13. (Continued). 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Quartile 4 v. 1 1.465 0.898 2.389 
Quartile 3 v. 1 1.007 0.611 1.661 
Quartile 2 v. 1 1.072 0.673 1.707 
 
 
 
 
Figure 14. Odds of being obese in relation to blood concentration of BDE-47. No comparisons 
yielded significant odds of obese BMI. 
 
 
Table 14. Odds of being obese in relation to blood concentration of BDE-47. 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Female v. Male 1.737 1.251 2.412 
Age in Years 1.002 0.993 1.011 
High v. Low Triglycerides  2.081 1.371 3.159 
High v. Low LDL 0.580 0.339 0.994 
OtherRace & Multiracial v. Mexican 
American 
0.309 0.116 0.820 
NonHispanic Black v.  Mexican American 1.307 0.800 2.136 
1.737 1.002 2.081 0.580 0.309 1.307 0.671 0.484 1.195 1.560 1.655
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Table 14. (Continued). 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
NonHispanic White v.  Mexican American 0.671 0.443 1.017 
Other Hispanic v.  Mexican American 0.484 0.163 1.443 
Quartile 4 v. 1 1.195 0.722 1.978 
Quartile 3 v. 1 1.560 0.949 2.565 
Quartile 2 v. 1 1.655 1.035 2.645 
              
4.2.2 BDE-99                          
4.2.2.1 Frequency Distributions 
 
 
Figure 15. Frequency distribution of BDE-99 per quartile range. 
 
 
Table 15. Frequency distribution table of BDE-99 per quartile range. 
 
BDE-99 (Quartiles)   
Concentration Range Frequency Percent Min Max 
Q1 (0-1.7) 569 24.35% 0.004949747 692 
Q2 (1.7-3.6) 593 25.37%   
Q3 (3.6-8.9) 594 25.42%   
Q4 (8.9-692) 581 24.86%   
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Table 16. Frequency distribution table of age ranges cross-referenced with BDE-99 quartiles. 
RIDADEYR refers to age in years from the 2003-2004 NHANES Demographic dataset and 
LBXBR5LA refers to BDE-99 from the 2003-2004 NHANES Brominated Flame Retardants 
dataset. 
 
 
            
 
Table 17. Frequency distribution table of gender cross-referenced with BDE-99 quartiles. 
RIAGENDR refers to gender from the 2003-2004 NHANES Demographic dataset and 
LBXBR5LA refers to BDE-99 from the 2003-2004 NHANES Brominated Flame Retardants 
dataset. 
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Table 18. Frequency distribution table of ethnicity cross-referenced with BDE-99 quartiles. 
RIDRETH1 refers to CDC-defined ethnicity from the 2003-2004 NHANES Demographic 
dataset and LBXBR5LA refers to BDE-99 from the 2003-2004 NHANES Brominated Flame 
Retardants dataset. 
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4.2.2.2 Comparative Statistics  
 
 
 
Figure 16. Comparison of average BDE-99 concentrations among age groups, in years. 
Difference in mean BDE-99 concentrations between age groups were insignificant; p-value 
>0.05. 
 
 
Table 19. Comparison of average BDE-99 concentrations among age groups, in years. 
 
Age Group, in years 12 to 18 19 to 30 31 to 50 51 to 84 85 and 
Above 
Concentrations, in ng/g 
lipids 
10.058 11.795 11.873 10.421 14.814 
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Figure 17. Comparison of average BDE-99 concentrations among genders. Difference in mean 
BDE-99 concentrations between genders were significant; p-value <0.05. 
 
 
Table 20. Comparison of average BDE-99 concentrations among genders. 
 
Gender Male Female 
Concentrations, in ng/g 
lipids 
12.793 9.365 
 
 
 
 
Figure 18. Comparison of average BDE-99 concentrations among ethnic groups. Difference in 
mean BDE-99 concentrations between ethnicities were insignificant; p-value >0.05. 
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Table 21. Comparison of average BDE-99 concentrations among ethnic groups. 
 
Ethnicity Mexican 
American 
Other 
Hispanic 
Non-
Hispanic 
White 
Non-
Hispanic 
Black 
Other Race - 
Including Multi-
Racial 
Concentrations, 
in ng/g lipids 
9.840 7.984 11.025 12.776 9.387 
 
 
 
 
Figure 19. Comparison of average BDE-99 concentrations among gender and ethnicities. 
Difference in average BDE-99 concentrations is insignificant, given genders & ethnicities; p-
value >0.05. 
 
 
Table 22. Comparison of average BDE-99 concentrations among gender and ethnicities. 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Mexican_Male 11.252 
OtherHispanic_Male 9.289 
White_Male 12.466 
Black_Male 15.451 
OtherRace/Multiracial_Male 11.221 
Mexican_Female 8.497 
11.252 9.289 12.466
15.451 11.221 8.497 6.814 9.697 10.181 8.077
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Table 22. (Continued). 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
White_Female 9.697 
Black_Female 10.181 
OtherRace/Multiracial_Female 8.077 
 
 
 
 
Figure 20. Comparison of average BDE-99 concentrations among males and ethnicities. 
Difference in average BDE-99 concentrations is insignificant, given males & ethnicities; p-value 
>0.05. 
 
 
Table 23. Comparison of average BDE-99 concentrations among males and ethnicities. 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Mexican_Male 11.252 
OtherHispanic_Male 9.289 
White_Male 12.466 
Black_Male 15.451 
OtherRace/Multiracial_Male 11.221 
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Figure 21. Comparison of average BDE-99 concentrations among females and ethnicities. 
Difference in average BDE-99 concentrations is insignificant, given females & ethnicities; p-
value >0.05. 
 
 
Table 24. Comparison of average BDE-99 concentrations among females and ethnicities. 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Mexican_Female 8.497 
OtherHispanic_Female 6.814 
White_Female 9.697 
Black_Female 10.181 
OtherRace/Multiracial_Female 8.077 
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4.2.2.3 Logistic Regression Statistics  
 
 
 
Figure 22. Odds of being overweight in relation to blood concentration of BDE-99. From a 
logistic regression model containing Gender, Age, Ethnicity and Quartiles as exposure variables 
and Overweight BMI as the outcome, Ethnicity is the only significant exposure variable which 
increases the odds of being overweight. Most interestingly is the 1.833 odds ratio produced for 
Other Hispanic (non-Mexican) Vs. Mexican categories. 
 
 
Table 25. Odds of being overweight in relation to blood concentration of BDE-99. 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Female v. Male 0.715 0.515 0.992 
Age in Years 1.008 0.999 1.017 
High v. Low Triglycerides  1.308 0.859 1.992 
High v. Low LDL 1.322 0.799 2.188 
OtherRace & Multiracial v. Mexican 
American 
0.607 0.241 1.528 
NonHispanic Black v.  Mexican American 0.777 0.461 1.308 
 
0.715 1.008 1.308 1.322 0.607 0.777 0.958 1.833 1.409 0.976 1.033
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Table 25. (Continued). 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
NonHispanic White v.  Mexican American 0.958 0.630 1.458 
Other Hispanic v.  Mexican American 1.833 0.699 4.804 
Quartile 4 v. 1 1.409 0.849 2.338 
Quartile 3 v. 1 0.976 0.590 1.615 
Quartile 2 v. 1 1.033 0.638 1.673 
 
 
 
 
Figure 23. Odds of being obese in relation to blood concentration of BDE-99. No comparisons 
yielded significant odds of obese BMI. 
 
 
Table 26. Odds of being obese in relation to blood concentration of BDE-99. 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Female v. Male 1.745 1.257 2.423 
Age in Years 1.002 0.993 1.010 
High v. Low Triglycerides  2.166 1.422 3.301 
High v. Low LDL 0.616 0.358 1.059 
    
1.745 1.002 2.166 0.616 0.308 1.265 0.652 0.476 1.002 1.156 1.285
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Table 26. (Continued). 
     
Effect Odds 
Ratio 
95% Confidence 
Intervals 
OtherRace & Multiracial v. Mexican 
American 
0.308 0.116 0.817 
NonHispanic Black v.  Mexican American 1.265 0.775 2.065 
NonHispanic White v.  Mexican American 0.652 0.430 0.987 
Other Hispanic v.  Mexican American 0.476 0.160 1.415 
Quartile 4 v. 1 1.002 0.598 1.677 
Quartile 3 v. 1 1.156 0.701 1.904 
Quartile 2 v. 1 1.285 0.796 2.075 
 
         
4.2.3 Sum of PBDEs                         
4.2.3.1 Frequency Distributions  
 
 
Figure 24. Frequency distribution of the sum of PBDEs per quartile range. 
 
 
Table 27. Frequency distribution table of the sum of PBDEs per quartile range. 
 
Sum of 10 PBDEs (Quartiles)   
Concentration Range Frequency Percent Min Max 
Q1 (0-16.5) 585 25.03% 0.044901281 3676.204667 
Q2 (16.5-35.8) 583 24.95%   
Q3 (35.8-77.3) 584 24.99%   
Q4 (77.3-3676.2) 585 25.03%   
585 583 584 585
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Table 28. Frequency distribution table of age ranges cross-referenced with total PBDE quartiles.  
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Table 29. Frequency distribution table of gender cross-referenced with total PBDE quartiles. 
 
 
 
 
Table 30. Frequency distribution table of ethnicity cross-referenced with total PBDE quartiles. 
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4.2.3.2 Comparative Statistics   
 
 
 
Figure 25. Comparison of average PBDE concentrations among age groups, in years. Difference 
in mean PBDE concentrations between age groups were insignificant; p-value >0.05. 
 
 
Table 31. Comparison of average PBDE concentrations among age groups, in years. 
 
Age Group, in years 12 to 18 19 to 30 31 to 50 51 to 84 85 and 
Above 
Concentrations, in ng/g 
lipids 
76.134 81.089 78.433 84.654 104.898 
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Figure 26. Comparison of average PBDE concentrations among genders. Difference in mean 
PBDE concentrations between genders were significant; p-value <0.05. 
 
 
Table 32. Comparison of average PBDE concentrations among genders. 
 
Gender Male Female 
Concentrations, in ng/g 
lipids 
93.780 68.599 
 
 
 
 
Figure 27. Comparison of average PBDE concentrations among ethnic groups. Difference in 
mean PBDE concentrations between ethnicities were insignificant; p-value >0.05. 
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Table 33. Comparison of average PBDE concentrations among ethnic groups. 
 
Ethnicity Mexican 
American 
Other 
Hispanic 
Non-
Hispanic 
White 
Non-
Hispanic 
Black 
Other Race - 
Including 
Multi-Racial 
Concentration
s, in ng/g lipids 
71.607 59.555 85.321 86.671 64.954 
 
 
 
 
Figure 28. Comparison of average PBDE concentrations among gender and ethnicities. 
Difference in average PBDE concentrations is insignificant, given genders & ethnicities; p-value 
>0.05. 
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Table 34. Comparison of average PBDE concentrations among gender and ethnicities. 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Mexican_Male 79.240 
OtherHispanic_Male 74.493 
White_Male 97.469 
Black_Male 105.795 
OtherRace/Multiracial_Male 77.755 
Mexican_Female 64.348 
OtherHispanic_Female 46.148 
White_Female 74.130 
Black_Female 68.126 
OtherRace/Multiracial_Female 55.810 
 
 
 
 
Figure 29. Comparison of average PBDE concentrations among males and ethnicities. 
Difference in average PBDE concentrations is insignificant, given males & ethnicities; p-value 
>0.05. 
 
 
Table 35. Comparison of average PBDE concentrations among males and ethnicities. 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Mexican_Male 79.240 
OtherHispanic_Male 74.493 
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Table 35. (Continued). 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Black_Male 105.795 
OtherRace/Multiracial_Male 77.755 
 
 
 
 
Figure 30. Comparison of average PBDE concentrations among females and ethnicities. 
Difference in average PBDE concentrations is insignificant, given females & ethnicities; p-value 
>0.05. 
 
 
Table 36. Comparison of average PBDE concentrations among females and ethnicities. 
 
Ethnicity & Gender Concentrations, 
in ng/g lipids 
Mexican_Female 64.348 
OtherHispanic_Female 46.148 
White_Female 74.130 
Black_Female 68.126 
OtherRace/Multiracial_Female 55.810 
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4.2.3.3 Logistic Regression Statistics   
 
 
 
Figure 31. Odds of being overweight in relation to blood concentration of PBDEs. From a 
logistic regression model containing Gender, Age, Ethnicity and Quartiles as exposure variables 
and Overweight BMI as the outcome, Ethnicity is the only significant exposure variable which 
increases the odds of being overweight. Most interestingly is the 1.871 odds ratio produced for 
Other Hispanic (non-Mexican) Vs. Mexican categories. 
 
 
Table 37. Odds of being overweight in relation to blood concentration of PBDEs. 
 
Effect Odds Ratio 95% Confidence 
Intervals 
Female v. Male 0.728 0.525 1.011 
Age in Years 1.008 0.999 1.017 
High v. Low Triglycerides  1.310 0.863 1.987 
High v. Low LDL 1.312 0.798 2.157 
OtherRace & Multiracial v. Mexican 
American 
0.615 0.244 1.549 
NonHispanic Black v.  Mexican American 0.759 0.450 1.280 
NonHispanic White v.  Mexican American 0.945 0.621 1.438 
Other Hispanic v.  Mexican American 1.871 0.711 4.925 
Quartile 4 v. 1 1.482 0.929 2.363 
0.728 1.008 1.310 1.312 0.615 0.759 0.945 1.871 1.482 0.821 1.054
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Table 37. (Continued). 
 
Effect Odds Ratio 95% Confidence 
Intervals 
Quartile 3 v. 1 0.821 0.501 1.347 
Quartile 2 v. 1 1.054 0.665 1.672 
 
 
 
 
Figure 32. Odds of being obese in relation to blood concentration of PBDEs. No comparisons 
yielded significant odds of obese BMI. 
 
 
Table 38. Odds of being obese in relation to blood concentration of PBDEs. 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Female v. Male 1.728 1.243 2.402 
Age in Years 1.002 0.993 1.011 
High v. Low Triglycerides  2.157 1.418 3.281 
High v. Low LDL 0.597 0.349 1.022 
OtherRace & Multiracial v. Mexican 
American 
0.299 0.112 0.796 
NonHispanic Black v.  Mexican American 1.322 0.807 2.165 
NonHispanic White v.  Mexican American 0.668 0.441 1.011 
Other Hispanic v.  Mexican American 0.522 0.175 1.558 
Quartile 4 v. 1 1.043 0.643 1.694 
1.728 1.002 2.157 0.597 0.299 1.322 0.668 0.522 1.043 1.239 1.839
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Table 38. (Continued). 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Quartile 3 v. 1 1.239 0.761 2.017 
Quartile 2 v. 1 1.839 1.161 2.912 
 
           
4.3 Dioxin-Like Polychlorinated Biphenyls              
4.3.1 Frequency Distributions    
 
 
 
Figure 33. Frequency distribution of the sum of dl-PCBs per quartile range. 
 
 
Table 39. Frequency distribution table of the sum of dl-PCBs per quartile range. 
 
Sum of DL-PCBs (Quartiles)   
Concentration Range Frequency Percent Min Max 
Q1 (1.300-4.5976) 431 25.01% 1.3001 358.8613 
Q2 (4.5978  -9.414) 430 24.96%   
Q3 (9.432-22.315) 431 25.01%   
Q4 (22.405 -358.862) 431 25.01%   
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Table 40. Frequency distribution table of age ranges cross-referenced with total dl-PCB 
quartiles.  
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Table 41. Frequency distribution table of gender cross-referenced with total dl-PCB quartiles.  
 
 
 
 
Table 42. Frequency distribution table of ethnicities cross-referenced with total dl-PCB 
quartiles.  
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4.3.2 Comparative Statistics  
 
 
 
Figure 34. Comparison of average dl-PCB concentrations among age groups, in years. 
Difference in mean DL-PCB concentrations between age groups were significant; p-value <0.05. 
 
 
Table 43. Comparison of average dl-PCB concentrations among age groups, in years. 
 
Age, in years 12 to 18 19 to 30 31 to 50 51 to 84 85 and 
Above 
Concentrations, ng/g 
lipids 
5.652 6.578 15.025 39.665 75.020 
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Figure 35. Comparison of average dl-PCB concentrations among genders. Difference in mean 
DL-PCB concentrations between genders were insignificant; p-value >0.05. 
 
 
Table 44. Comparison of average dl-PCB concentrations among genders. 
 
Gender Male Female 
Concentrations, ng/g 
lipids 
17.987 20.635 
 
 
 
 
Figure 36. Comparison of average dl-PCB concentrations among ethnic groups. Difference in 
mean DL-PCB concentrations between races were significant; p-value <0.05. Non-Hispanic 
White vs. Mexican American and Non-Hispanic Black vs. Mexican American PBDE 
concentrations were the significant comparisons. 
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Table 45. Comparison of average dl-PCB concentrations among ethnic groups. 
 
Ethnicity Mexican 
American 
Other 
Hispanic 
Non-
Hispanic 
White 
Non-
Hispanic 
Black 
Other Race - Including 
Multi-Racial 
Concentrations, 
ng/g lipids 
10.477 17.784 22.957 20.946 19.235 
 
 
 
 
Figure 37. Comparison of average dl-PCB concentrations among gender and ethnicities. 
Difference in average DL-PCB concentrations is significant, among genders & ethnicities; p-
value <0.05. According to Tukey’s test, a comparison of average DL-PCB concentrations of 
White_Male v. Mexican_Male, and Black_Male v. Mexican_Male groups were significant and a 
comparison of average DL-PCB concentrations of Black_Female v. Mexican_Female, and 
White_Female v. Mexican_Female groups were significant. 
 
 
Table 46. Comparison of average dl-PCB concentrations among gender and ethnicities. 
 
Ethnicity Concentrations, 
ng/g lipids 
Mexican_Male 8.811 
OtherHispanic_Male 15.358 
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Table 46. (Continued). 
  
Ethnicity Concentrations, 
ng/g lipids 
Black_Male 18.109 
OtherRace/Multiracial_Male 20.708 
Mexican_Female 12.003 
OtherHispanic_Female 19.776 
White_Female 23.668 
Black_Female 23.853 
OtherRace/Multiracial_Female 17.562 
 
   
 
 
Figure 38. Comparison of average dl-PCB concentrations among males and ethnicities. 
According to Tukey’s test, a comparison of average DL-PCB concentrations of White_Male v. 
Mexican_Male, and Black_Male v. Mexican_Male groups were significant. 
 
 
Table 47. Comparison of average dl-PCB concentrations among males and ethnicities. 
 
Ethnicity Mexican_
Male 
OtherHispanic_
Male 
White_M
ale 
Black_M
ale 
OtherRace/Multiracia
l_Male 
Concentrations, 
ng/g lipids 
8.811 15.358 22.204 18.109 20.708 
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Figure 39. Comparison of average dl-PCB concentrations among females and ethnicities. 
According to Tukey’s test, a comparison of average DL-PCB concentrations of Black_Female v. 
Mexican_Female, and White_Female v. Mexican_Female groups were significant. 
 
 
Table 48. Comparison of average dl-PCB concentrations among females and ethnicities. 
 
Ethnicity Mexican
_Female 
OtherHispanic_Fe
male 
White_Fe
male 
Black_Fem
ale 
OtherRace/Multiracial_
Female 
Concentrations, 
ng/g lipids 
12.003 19.776 23.668 23.853 17.562 
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4.3.3 Logistic Regression Statistics   
 
 
 
Figure 40. Odds of being overweight in relation to blood concentration of dl-PCBs. From a 
logistic regression model containing Gender, Age, Ethnicity and Quartiles as exposure variables 
and Overweight BMI as the outcome, Ethnicity and LDL Cholesterol (High vs Low) differences 
are significant in increasing the odds of being overweight. Most interestingly is the 1.063 odds 
ratio produced for Other Hispanic (non-Mexican) Vs. Mexican, 1.075 odds ratio produced for 
Other Race Vs. Mexican categories, and 1.353 odds ratio produced for High LDL Cholesterol 
Vs. High LDL Cholesterol. 
 
 
Table 49. Odds of being overweight in relation to blood concentration of dl-PCBs. 
 
Effect Odds Ratio 95% Confidence 
Intervals 
Female v. Male 0.854 0.589 1.239 
Age in Years 1.023 1.008 1.037 
High v. Low Triglycerides  1.239 0.768 1.999 
High v. Low LDL 1.353 0.778 2.352 
OtherRace & Multiracial v. Mexican 
American 
1.075 0.417 2.769 
NonHispanic Black v.  Mexican American 0.873 0.453 1.682 
NonHispanic White v.  Mexican American 0.823 0.503 1.348 
Other Hispanic v.  Mexican American 1.063 0.345 3.272 
Quartile 4 v. 1 0.434 0.184 1.027 
0.854 1.023 1.239 1.353 1.075 0.873 0.823 1.063 0.434 0.658 0.663
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Table 49. (Continued). 
 
Effect Odds Ratio 95% Confidence 
Intervals 
Quartile 3 v. 1 0.658 0.319 1.358 
Quartile 2 v. 1 0.663 0.331 1.326 
 
 
 
 
Figure 41. Odds of being obese in relation to blood concentration of dl-PCBs. No comparisons 
yielded significant odds of obese BMI. 
 
 
Table 50. Odds of being obese in relation to blood concentration of dl-PCBs. 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Female v. Male 1.379 0.941 2.020 
Age in Years 0.991 0.976 1.005 
High v. Low Triglycerides  1.600 0.989 2.589 
High v. Low LDL 1.129 0.633 2.012 
OtherRace & Multiracial v. Mexican 
American 
0.331 0.112 0.980 
NonHispanic Black v.  Mexican American 1.287 0.685 2.418 
NonHispanic White v.  Mexican American 0.575 0.350 0.943 
1.379 0.991 1.600 1.129 0.331 1.287 0.575 0.477 1.395 1.405 0.978
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Table 50. (Continued). 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Other Hispanic v.  Mexican American 0.477 0.140 1.632 
Quartile 4 v. 1 1.395 0.591 3.293 
Quartile 3 v. 1 1.405 0.679 2.906 
Quartile 2 v. 1 0.978 0.488 1.958 
 
            
4.4 Phthalates                 
4.4.1 Frequency Distributions   
 
 
Figure 42. Frequency distribution of the sum of phthalates per quartile range. 
 
 
Table 51. Frequency distribution table of the sum of phthalates per quartile range. 
 
Sum of Phthalates (Quartiles)   
Concentration Range Frequency Percent Min Max 
Q1 (9-183.42) 565 100.00% 9.282631811 31733.40514 
Q2 (183.49-369.54 ) 566 0.00%   
Q3 (369.77 -776.19) 566 0.00%   
Q4 (776.94 -31734) 566 0.00%   
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Table 52. Frequency distribution table of age ranges cross-referenced with total phthalate 
quartiles.  
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Table 53. Frequency distribution table of gender cross-referenced with total phthalate quartiles.  
 
 
 
 
 
Table 54. Frequency distribution table of ethnicities cross-referenced with total phthalate 
quartiles.  
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4.4.2 Comparative Statistics   
 
 
 
Figure 43. Comparison of average phthalate concentrations among age groups, in years. 
Difference in mean Phthalate concentrations between age groups were significant; p-value <0.05 
 
 
Table 55. Comparison of average phthalate concentrations among age groups, in years. 
 
Age Group, in years 12 to 18 19 to 30 31 to 50 51 to 84 85 and 
Above 
Concentrations, in ng/g 
lipids 
791.161 898.867 826.693 688.263 397.113 
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Figure 44. Comparison of average phthalate concentrations among genders. Difference in mean 
phthalate concentrations between genders were insignificant; p-value >0.05. 
 
 
Table 56. Comparison of average phthalate concentrations among genders. 
 
Gender Male Female 
Concentrations, in ng/g 
lipids 
835.662 727.169 
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Figure 45. Comparison of average phthalate concentrations among ethnic groups. Difference in 
mean Phthalate concentrations between races were significant; p-value <0.05. 
 
 
Table 57. Comparison of average phthalate concentrations among ethnic groups. 
 
Ethnicity Mexican 
American 
Other 
Hispanic 
Non-
Hispanic 
White 
Non-
Hispanic 
Black 
Other Race - Including 
Multi-Racial 
Concentrations, in 
ng/g lipids 
763.812 1086.998 626.326 1061.037 552.166 
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Figure 46. Comparison of average phthalate concentrations among gender and ethnicities. 
According to Tukey’s test, a comparison of average phthalate concentrations of 
OtherHispanic_Male and Black_Male groups was significant and a comparison of average 
phthalate concentrations of OtherHispanic_Female and  White_Female, Black_Female and 
Mexican_Female, Black_Female and White Female were significant. 
 
 
Table 58. Comparison of average phthalate concentrations among gender and ethnicities. 
 
Ethnicity Concentrations, 
in ng/g lipids 
Mexican_Male 852.102 
OtherHispanic_Male 920.440 
White_Male 711.763 
Black_Male 1060.784 
OtherRace/Multiracial_Male 567.649 
Mexican_Female 679.306 
OtherHispanic_Female 1244.552 
White_Female 547.704 
Black_Female 1061.277 
OtherRace/Multiracial_Female 540.984 
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Figure 47. Comparison of average phthalate concentrations among males and ethnicities. 
According to Tukey’s test, a comparison of average phthalate concentrations of 
OtherHispanic_Male and Black_Male groups was significant. 
 
 
Table 59. Comparison of average phthalate concentrations among males and ethnicities. 
 
Ethnicity Mexican_M
ale 
OtherHispanic_
Male 
White_M
ale 
Black_M
ale 
OtherRace/Multiracial
_Male 
Concentrations, 
in ng/g lipids 
852.102 920.440 711.763 1060.784 567.649 
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Figure 48. Comparison of average phthalate concentrations among females and ethnicities. 
According to Tukey’s test, a comparison of average phthalate concentrations of 
OtherHispanic_Female and White_Female, Black_Female and Mexican_Female, Black_Female 
and White Female were significant. 
 
 
Table 60. Comparison of average phthalate concentrations among females and ethnicities. 
 
Ethnicity Mexican_Fe
male 
OtherHispanic_F
emale 
White_Fe
male 
Black_Fe
male 
OtherRace/Multiracial
_Female 
Concentration
s, in ng/g lipids 
679.306 1244.552 547.704 1061.277 540.984 
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4.4.3 Logistic Regression Statistics   
 
 
 
Figure 49. Odds of being overweight in relation to urinary concentration of phthalates.  
 
 
Table 61. Odds of being overweight in relation to urinary concentration of phthalates. 
 
Effect Odds Ratio 95% Confidence 
Intervals 
Female v. Male 0.715 0.514 0.994 
Age in Years 1.010 1.001 1.019 
High v. Low Triglycerides  1.319 0.869 2.001 
High v. Low LDL 1.304 0.790 2.152 
OtherRace & Multiracial v. Mexican 
American 
0.666 0.263 1.685 
NonHispanic Black v.  Mexican American 0.825 0.489 1.392 
NonHispanic White v.  Mexican American 0.967 0.636 1.472 
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Figure 50. Odds of being obese in relation to urinary concentration of phthalates. 
 
 
Table 62. Odds of being obese in relation to urinary concentration of phthalates. 
 
Effect Odds 
Ratio 
95% Confidence 
Intervals 
Female v. Male 1.810 1.297 2.525 
Age in Years 1.002 0.993 1.011 
High v. Low Triglycerides  2.170 1.427 3.298 
High v. Low LDL 0.609 0.355 1.047 
OtherRace & Multiracial v. Mexican 
American 
0.340 0.127 0.913 
NonHispanic Black v.  Mexican American 1.248 0.761 2.048 
NonHispanic White v.  Mexican American 0.675 0.446 1.024 
Other Hispanic v.  Mexican American 0.496 0.167 1.470 
Quartile 4 v. 1 1.702 1.057 2.740 
Quartile 3 v. 1 1.127 0.705 1.800 
Quartile 2 v. 1 1.089 0.690 1.721 
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4.5 Comparison of Analytes  
 
 
 
Figure 51. Comparison of average PBDE (in blue) and dl-PCB (in red) concentrations among 
age-groups. Approximately 22.5% of the total variation in y can be explained by the linear 
relationship between x and y (as described by the regression equation). A positive moderate 
association exists between concentrations of PBDEs and dl-PCBs among age groups; R=0.47. 
Finally, p-value<0.05; there is a significant difference in the average concentrations of PBDEs in 
comparison to dl-PCBs’, among age groups. 
 
 
Table 63. Comparison of average PBDE and dl-PCB concentrations among age-groups. 
 
Age 
Groups 
Ages Mean PBDE Concentrations (ppb) Mean dl-PCB 
Concentrations (ppb) 
1 12 to 18 76.134 5.652 
2 19 to 30 81.089 6.578 
3 31 to 50 78.433 15.025 
4 51 to 84 84.654 39.665 
5 85 and Above 104.898 75.020 
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Figure 52. Comparison of average PBDE (in blue) and dl-PCB (in red) concentrations among 
genders. Approximately 3.1% of the total variation in y can be explained by the linear 
relationship between x and y (as described by the regression equation). A negative but very weak 
association exists between concentrations of PBDEs and dl-PCBs among genders; R=0.17. 
Finally, p-value>0.05; there is no significant difference in the average concentrations of PBDEs 
in comparison to dl-PCBs’, among gender groups. 
 
 
Table 64. Comparison of average PBDE and dl-PCB concentrations among genders. 
 
Gender 
Groups 
Genders  Mean PBDE 
Concentrations (ppb) 
Mean dl-PCB 
Concentrations 
(ppb) 
1 Male 93.780 17.987 
2 Female 68.599 20.635 
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Figure 53. Comparison of average PBDE (in blue) and dl-PCB (in red) concentrations among 
ethnicities. Approximately 0.7% of the total variation in y can be explained by the linear 
relationship between x and y (as described by the regression equation). A positive but very weak 
association exists between concentrations of PBDEs and dl-PCBs among ethnicities; R=0.08. 
Finally, p-value<0.05; there is a significant difference in the average concentrations of PBDEs in 
comparison to dl-PCBs’, among ethnic groups. 
 
 
Table 65. Comparison of average PBDE and dl-PCB concentrations among ethnicities. 
 
Ethnic 
Groups 
Ethnicities  Mean PBDE 
Concentrations (ppb) 
Mean dl-PCB 
Concentrations 
(ppb) 
1 Mexican American 71.607 10.477 
2 Other Hispanic 59.555 17.784 
3 Non-Hispanic White 85.321 22.957 
4 Non-Hispanic Black 86.671 20.946 
5 Other 
Race/MultiRacial 
64.954 19.235 
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4.6 Summary of Results  
Summary of PBDE Results 
• Mean PBDE concentrations are significantly different among genders 
o For sum, BDE-47, BDE-99  
• Mean PBDE concentrations are not significantly different among age groups, 
ethnicities 
o For sum, BDE-47, BDE-99  
• Based on categorical analysis,  
o Ethnicity is the only significant predictor of overweight BMI 
o Although, confidence intervals were generally large 
o No significant results were found for obesity analyses 
• The difference in PBDE blood concentrations was insignificant when accounting 
for genders and ethnicities. 
 
Summary of dl-PCB Results 
• Mean PCB concentrations are significantly different among age groups and 
ethnicities 
• Mean PCB concentrations are not significantly different among genders 
• Based on categorical analysis 
o Ethnicity and LDL cholesterol are predictors of overweight BMI 
o Although, confidence intervals were generally large 
o No significant results were found for obesity analysis 
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• The difference in PCB concentrations were significant among gender and 
ethnicities, males and ethnicities, and females and ethnicities. 
 
Summary of phthalate Results 
• Mean Phthalate concentrations are significantly different among age groups and 
ethnicities. 
• Mean Phthalate concentrations are not significantly different among genders. 
• Based on categorical analysis, 
o Ethnicity is the only significant predictor of overweight BMI. 
o Although, confidence intervals were generally large. 
o No significant results were found for obesity analysis. 
• The difference in Phthalate concentrations were significant among gender and 
ethnicities. 
 
Summary of Analyte Comparison Results 
• Mean	concentrations	among	age	groups,	in	parts	per	billion,	differed	significantly	between	PBDEs	and	dl-PCBs.	
• Mean	concentrations	among	genders,	in	parts	per	billion,	did	not	differ	significantly	between	PBDEs	and	dl-PCBs.	
• Mean	concentrations	among	ethnicities,	in	parts	per	billion,	differed	significantly	between	PBDEs	and	dl-PCBs.	
o Blood	serum	concentrations	of	PBDEs	was	generally	higher	than	dl-PCBs	in	analyses	of	age	groups,	genders	and	ethnicities.	 	
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Chapter 5 
Discussion 
5.1 Evaluation of Research Hypotheses  
The proposed hypotheses of this dissertation research will be examined below, to determine how 
well the results of this study supported the overall objectives of this research:    
 
Hypothesis 1: Biomonitoring data obtained from the National Health and Nutrition Examination 
Survey indicates the presence of background biomarkers of PBDE, dl-PCB, and phthalate 
exposure in individuals from a sample of the general population. 
 
Through the analyses that were conducted using the Demographic Variables & Sample 
Weights, Phthalates, and Dioxins, Furans, & Coplanar PCBs, there is evidence that PBDE, dl-PCB 
and Phthalate biomarkers are present in a sample of the US population. However, one must 
remember that the metabolism of pollutants can vary among study participants (Manno et al., 
2010). The latter has an impact on the reported concentrations of each analyte. In addition, one 
should consider the impact of dilution on reported analyte concentrations, especially in the case of 
urinary phthalates.  
 
Hypothesis 2: Due to the bioaccumulative properties of PBDEs in the human body, increasing 
PBDE concentrations is significantly associated with increasing with age groups.  
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• Due	to	the	bioaccumulative	properties	of	dl-PCBs	in	the	human	body,	increasing	dl-PCB	
concentrations	is	significantly	associated	with	increasing	with	age	groups.		
• Due	 to	 the	 bioaccumulative	 properties	 of	 phthalates	 in	 the	 human	 body,	 increasing	
phthalate	concentrations	is	significantly	associated	with	increasing	with	age	groups.	
 
A comparison of the average concentrations of PBDEs among age groups reveal that 
concentrations of the sum of PBDEs, BDE-47, and BDE-99 are not significantly associated with 
increasing age groups. The opposite results were found in an analysis of the distribution of dl-PCB 
and phthalate concentrations among age groups. It is not known why such differences in 
distributions exist since all three compounds are known to accumulate in the body over time. In 
the case of dl-PCBs, an exponential increase in concentration with increasing age groups was 
observed which supports the notion that these contaminants have a relatively long half-life in 
comparison to PBDEs. In the case of phthalates, urinary concentrations generally decrease with 
age. Furthermore, participants aged 85 or older have urinary concentrations that are, on average, 
lower in comparison to other age groups. Additionally, it should be noted that the age groups were 
arbitrarily divided. Hence, different conclusions and trends could have been generated if much 
different age groups were selected. Also, since the dataset is limited to ages 12 – 85 years, it is not 
known whether different conclusions would have been generated if the NHANES survey of these 
contaminants included individuals of a broader age range (e.g., including participants younger than 
12 years old). 
 
Hypothesis 3: Since PBDEs are ubiquitous in the environment, the average concentrations of its 
biomarkers are homogeneous across other sample subgroups including genders, ethnicities, and, 
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genders and ethnicities; indicating that these subgroups are not at an increased risk of a negative 
health outcome. 
• Similarly, average dl-PCB concentrations are homogeneous across other sample 
subgroups including genders, ethnicities, and, genders and ethnicities; indicating that 
these subgroups are not at an increased risk of a negative health outcome. 
• Similarly, average phthalate concentrations are homogeneous across other sample 
subgroups including genders, ethnicities, and, genders and ethnicities; indicating that 
these subgroups are not at an increased risk of a negative health outcome. 
 
Concerning the analysis of other demographic categories, including gender, ethnicities and 
gender with ethnicities significant differences were observed for all analytes of interest. First, the 
average PBDE concentrations reported for the sum of PBDEs, BDE-47 and BDE-99 were 
significantly different among genders. In fact, males consistently had significantly higher average 
concentrations of the sum of PBDEs, BDE-47 and BDE-99. This is likely due to toxicokinetic 
(e.g., absorption, metabolism and elimination) differences among genders. The opposite was found 
in the case of dl-PCBs and phthalates. Once again it is not known why PBDEs are distributed 
differently than dl-PCBs and phthalates, among genders. In fact, a similar difference was found 
when analyzing the concentrations of these analytes among ethnicities. Specifically, the average 
concentrations of the sum of PBDEs, BDE-47, and BDE-99 were not significantly different among 
ethnicities. On the other hand, significantly different concentrations of dl-PCBs and phthalates 
were observed among ethnicities. Moreover, based on an analysis of the average concentrations of 
PBDEs, BDE-47 and BDE-99, there is no significant difference among genders and ethnicities 
(e.g., Black males v. Mexican American females). The latter supports part of the above-listed 
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hypothesis. However, when the analyses were conducted for the other contaminants, the opposite 
conclusions were found. Specifically, the difference in dl-PCB concentrations were significant 
among gender and ethnicities, males and ethnicities, and females and ethnicities. Also, the 
difference in phthalate concentrations were significant among gender and ethnicities; not for males 
and ethnicities, nor females and ethnicities. Tukey’s Test was used to determine which specific 
groups had significantly different concentrations for dl-PCBs and phthalates, using a 95% 
confidence level. According to Tukey’s test, a comparison of average dl-PCB concentrations of 
White_Male v. Mexican_Male, and Black_Male v. Mexican_Male groups were significant and a 
comparison of average dl-PCB concentrations of Black_Female v. Mexican_Female, and 
White_Female v. Mexican_Female groups were significant. Also, according to Tukey’s Test, a 
comparison of average phthalate concentrations of OtherHispanic_Male and Black_Male groups 
was significant and a comparison of average phthalate concentrations of OtherHispanic_Female 
and White_Female, Black_Female and Mexican_Female, Black_Female and White Female were 
significant. The significant outcomes that were discovered in the analyses of dl-PCB and phthalate 
concentrations could have been due to the oversampling of minorities through the NHANES 
program. As mentioned in the Methods section, the NHANES program oversamples minorities 
and the elderly since they tend to have drastically different health statuses and characteristics of 
concern, in comparison to non-minorities (CDC, 2012). However, one must note that this 
oversampling could lead to an overestimation of true exposure. Thus, the significant differences 
of dl-PCB and phthalate concentrations found among age groups, ethnicities, and genders with 
ethnicities could have been nullified if elderly and minority groups were not given special 
attention. The reported data could be overestimating the actual concentration of the biomarkers 
when extrapolating results to the population. In fact, true population levels may be lower than 
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those reported in the NHANEs sample (Lebeau, 2012). Finally, as a result of the consistency of 
results that have been observed between analytes, one can conclude that PBDEs appear to be 
distributed differently among demographic categories in comparison to dl-PCBs and phthalates. 
In contrast, when considering the homogeneity or heterogeneity of average dl-PCB and phthalate 
concentrations among various demographic categories, significance of results is similar for both 
types of compounds. These results suggest pharmacodynamic differences for PBDEs in 
comparison to dl-PCBs and phthalates. Correspondingly, these results also suggest possible 
pharmacodynamic similarities between dl-PCBs and phthalates. 
 
Hypothesis 4: Blood sample data from the National Health and Nutrition Examination Survey 
reveal that the background concentrations of PBDEs do not significantly increase the odds of 
obesity nor the odds of being overweight. 
a. Blood sample data from the National Health and Nutrition Examination Survey reveal 
that the background concentrations of dl-PCBs do not significantly increase the odds 
of obesity nor the odds of being overweight. 
b. Blood sample data from the National Health and Nutrition Examination Survey reveal 
that the background concentrations of phthalates do not significantly increase the 
odds of obesity nor the odds of being overweight. 
 
According to a categorical analysis of PBDEs and obesity, PBDE background 
concentrations (higher vs. lower quartiles) did not significantly increase participants’ odds of being 
obese. In fact, when considering age, gender, ethnicity, LDL cholesterol, triglycerides and PBDE 
quartiles in the logistic regression model no results were significant. In the case of overweight 
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status, ethnicity was the only significant predictor of overweight BMI. Next, analyses also show 
that the background concentrations of dl-PCBs did not significantly increase one’s odd of being 
obese or overweight. Ethnicity and LDL cholesterol were the only significant predictors of 
overweight BMI, when considering age, gender, ethnicity, LDL cholesterol, triglycerides and 
PBDE quartiles in the logistic regression model. Finally, background concentrations of phthalates 
did not significantly increase participant’s odds of obesity or of being overweight. Ethnicity was 
the only significant predictor of overweight BMI, when considering age, gender, ethnicity, LDL 
cholesterol, triglycerides and PBDE quartiles in the logistic regression model. Although, it should 
be noted that confidence intervals were generally large in all three sets of categorical analyses. 
 
Hypothesis 5: Due to the similarities of PBDEs and dl-PCBs, average concentrations are not 
significantly different among demographic categories. 
c. Although distributions of phthalate concentrations can be discussed in relation to 
PBDEs, specific comparisons cannot be made due to a difference in measurement units 
(ng/g lipids for PBDEs and dl-PCBs vs. ng/mL for phthalates).  
 
First, it should be reiterated that a direct comparison cannot be made between PBDEs and 
phthalates because unlike PBDEs and dl-PCBs which were measured in serum and reported in 
ng/g lipid, phthalates were measured in urine and reported in ng/mL. In other words, the prior were 
reported in weight/weight ratio whereas the latter was reported in weight/volume ratio. Due to 
mathematical convention, a direct comparison cannot be made between these two types of units. 
As a result, while the distributions of all three analytes were investigated, direct comparative 
analyses could only be conducted for the sum of PBDEs and the sum of dioxin-like PCBs. Based 
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on paired t-test analyses, the average concentrations of PBDEs were significantly different from 
the average concentrations of dl-PCBs, when considering age groups and ethnicities. Next, average 
concentrations of PBDEs and dl-PCBs did not significantly differ when considering genders. In 
general, PBDE blood serum concentrations were higher than dl-PCBs in analyses of age groups, 
genders and ethnicities. These results are likely due to the 1979 ban on polychlorinated biphenyls. 
Although PCBs are persistent in our environments and despite their relatively long half-lives, and 
ability to accumulate in the body, PBDEs have been the dominant flame retardants of since 
(Vonderheide et al., 2008). Hence, their presence in our environments is likely to be much more 
pronounced. 
 
5.2 Evaluation of Results               
Overall, the average PBDE concentration among participants in the 2003-2004 NHANES 
was approximately 81 ng/g lipid with a range of 0.05 (LOD/√2) to 3676 ng/g lipid. These results 
are not clearly comparable with those of other studies for several reasons. First, unlike other 
studies, the 2003-2004 NHANES survey provides one of the largest samples used to investigate 
polybrominated brominate diphenyl ethers. Most comparable studies have much more limited 
sample sizes. As a result, investigators often report concentrations that are on generally less than 
those found in this dissertation research. The range of reported results are also much different. For 
example, according to a study of a sum of 10 PBDEs, Eskenazi and company reported a range of 
4.2 to 1379.4 ng/g lipid in maternal serum and 6.9 to 1385.5 ng/g lipid in child serum, in a study 
of the neurodevelopment effects of PBDEs (Eskenazi et al., 2013). Investigators in this study and 
others often report the median as a measure of central tendency instead of the mean. This also 
makes it difficult to compare results of this study with others. Overall, comparisons are difficult to 
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make as a result in differences in congeners, statistical tests, sample size, sample medium (e.g., 
blood, milk, food, etc.) and demographic categories considered. Most studies report PBDE 
concentrations (in various media) specifically in nursing mothers and children. Thus, the results 
of such studies are not representative of the US population. 
 
Nonetheless, Schecter et al. conducted a 2003 study of the PBDE concentrations in 
American breast milk compared to women’s breast milk in other countries. Investigators analyzed 
13 PBDEs in 47 individual milk samples from Texan nursing mothers, aged 20 to 41 years old. 
Investigators reported a range of 6.2 to 419 ng/g lipid and a mean of 73.9 ng/g lipid. Furthermore, 
investigators postulate that their results are similar to concentrations found in American blood and 
adipose tissue from Indiana and California (including research by Zota et al.) which are 10 to 100 
times greater than PBDE concentrations found in France, Germany, and Russia. They also mention 
that most of the women were Caucasian. Hence, it may be more appropriate to compare their 
results to PBDE concentrations of White_Females in this dissertation research who had a 
comparable average PBDE concentration of 74.1 ng/g lipid. It should also be mentioned that since 
their research contained participants who were mostly Caucasian, their results are selectively 
biased (Schecter et al., 2003).   
 
5.3 Evaluation of Risk                        
In general, as a result of a lack of information pertaining to the dose, duration, exposure 
source and route biomonitoring data can be difficult to assume risk. The National Health and 
Nutrition Examination Survey does not provide such information, which can lead due to a 
misinterpretation of the results (Centers for Human Health Assessment, 2017; Lebeau, 2012; 
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Manno et al., 2010). Regardless of the latter, a reported concentration, even if it were above a 
permissible level, would not be sufficient evidence to suggest a health risk. In fact, some 
statistically significant results were observed when considering the average sum of PBDE, BDE-
47 and BDE-99 concentrations among genders. Males had consistently higher levels than females, 
in all three analyses. These results could suggest that males may be more at-risk than females to 
the potential health effects of PBDEs. However, this conclusion would likely be incorrect since, 
not only do measured concentrations not necessitate risk, a specific health outcome may be 
dependent on the phenotypic or genotypic characteristics of individuals. Moreover, the measured 
background concentrations may not lead to any health effects in the American population. In 
addition, although reference doses have been generated for some BDE congeners, such reference 
doses cannot be used to predict risk (IRIS, 2003; IRIS, 2004; IRIS, 2008a-d). They are created to 
protect people from potential and often unknown health effects. 
 
5.4 Limitations of the Research                        
This cross-sectional study using the NHANES survey yielded some significant results 
among various demographics, depending upon the contaminant of interest. Since risk assessment 
is a very important feature of toxicology, a longitudinal study would have been more appropriate 
for the assessment of health risks. A major benefit of the latter is that data would be gathered for 
the same subjects repeatedly over a period. This would allow us to monitor increases and decreases 
in PBDE concentration. On the other hand, the NHANEs cross-sectional study design only 
generates a snapshot of PBDE concentrations for different participants. In addition, since the 2003-
2004 NHANES dataset contained the most recent PBDE concentration data among Americans, 
this data is relatively dated. It would be useful to analyze recent data. However, NHANES has not 
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produced such a dataset since then. Next, it is unknown whether low dose, chronic exposure to 
PBDEs can cause adverse health effects. This makes the evaluation of dose-response difficult. As 
previously mentioned, minorities and the elderly were oversampled in this research. This may have 
introduced sampling bias into the analyses. Furthermore, there were 297 values that were below 
the limit of detection. These values were treated by dividing the LOD/√2. Other treatment methods 
which could have been used include LOD=0 and LOD/2. The LOD/√2 treatment method was 
automatically applied by the CDC for the dl-PCB dataset. Hence, for comparison’s sake, this 
method was also used for the other analytes in this dissertation research. It should also be 
mentioned that the all analyses for the sum of PBDEs, BDE-47 and BDE-99 were also performed 
using the LOD=0 and LOD/2 treatment methods for values that were below the detection limits of 
the analytical instruments. No significant differences were found among analyses. Finally, since 
electronic waste workers are often addressed as an occupational group with increased exposure to 
PBDEs, it would be worthwhile to assess their blood PBDE concentrations in addition to other 
demographics. However, these workers could not be categorized using the NHANES occupational 
subset due to the use of broad occupational and industry categories. In other words, electronic-
waste workers could not be separated from NHANES’ occupational or industry designations.  
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Chapter 6 
Conclusion 
Since the 1979 ban of polychlorinated biphenyls in the United States, production, 
importation and usage of polybrominated diphenyl ethers have grown tremendously due their cost 
effectiveness as flame retardants. However, PBDEs experienced a similar fate in December of 
2013 when their only US manufacturers and importers guaranteed a complete phase out of these 
flame retardants. This phase out occurred largely as a result of unsubstantiated public health 
concerns based on inconsistent literature.  
 
In fact, research pertaining to the most potential health effects of PBDEs have been very 
inconsistent. Most notably, previous studies have investigated measures of obesity in relation to 
PBDE exposure with a focus on pediatric populations. As mentioned in the Literature Review, the 
only applicable research is from Agay-Shay, Costa and Vuong et al. whose results have been 
conflicting at best. Moreover, no other study has focused primarily on the potential effects of 
PBDE exposure in relation to obesity and overweight status of American adults.  
 
Therefore, to address current research gaps, this study investigated the human blood 
concentrations of PBDEs among demographic categories generated through the 2003-2004 
NHANES. Analyses of this representative sample of the American population revealed detectable 
concentrations of PBDEs ranging from 0.05 to 3676 ng/g lipid. Among the various demographic 
categories that were analyzed, PBDE concentrations per gender yielded the only significant results 
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for the sum of PBDEs, BDE-47 and BDE-99. In addition, PBDEs did not lead to a higher odd of 
being obese or overweight. These analyses were repeated for dioxin-like polychlorinated biphenyls 
and phthalates. In general, analyses of dl-PCBs and phthalates among demographic categories 
produced similar significant results which opposed those of PBDE analyses. Overall, no analytes 
led to a significant odd of being obese or overweight. 
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Appendices 
 
Appendix I – Polybrominated Diphenyl Ethers Sampled 
 
PBDE Congeners in 2003-2004 NHANES 
 
Name of 
Congener 
Compound SAS name 
(lipid-
adjusted) 
Limits of 
Detection 
in ppb 
(NHANES 
Manual) 
LOD/√2* 
BDE-17 2,2',4-
tribromodiphenyl 
ether 
LBXBR1LA 0.0025 0.00176776695 
 
BDE-28 2,4,4'-
tribromodiphenyl 
ether 
LBXBR2LA 0.0025 0.00176776695 
 
BDE-47 2,2',4,4'-
tetrabromodiphenyl 
ether 
LBXBR3LA 
 
0.0062 0.00438406204 
BDE-66 2,3',4,4'-
tetrabromodiphenyl 
ether 
LBXBR66L 0.0028 0.00197989898 
BDE-85 2,2',3,4,4'-
pentabromodiphenyl 
ether 
LBXBR4LA 0.0164 0.01159655121 
BDE-99 2,2',4,4',5-
pentabromodiphenyl 
ether 
LBXBR5LA 0.007 0.00494974746 
BDE-100 2,2',4,4',6-
pentabromodiphenyl 
ether 
LBXBR6LA 0.0025 0.00176776695 
 
BDE-153 2,2',4,4',5,5'-
hexabromodiphenyl 
ether 
LBXBR7LA 0.017 0.01202081528 
BDE-154 2,2',4,4',5,6'-
hexabromodiphenyl 
ether 
LBXBR8LA 0.0025 0.00176776695 
 
BDE-183 2,2',3,4,4',5',6-
heptabromodiphenyl 
ether 
LBXBR9LA 0.0041 0.0028991378 
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*There were 297 values below the limit of detection. These values were divided by the square 
root of two and manually inserted into the master dataset. 
 
Appendix II – Dioxin-Like Polychlorinated Biphenyls Sampled 
 
Dioxin-Like PCBs in 2003-2004 NHANES 
 
Name of 
Congener 
Chemical Name SAS Name 
(Lipid 
Adjusted)* 
PCB 105 2,3,3',4,4'-
Pentachlorobiphenyl  
LBX105LA 
PCB 118 2,3',4,4',5-
Pentachlorobiphenyl  
LBX118LA 
PCB 156 2,3,3',4,4',5-
Hexachlorobiphenyl  
LBX156LA 
PCB 157 2,3,3',4,4',5'-
Hexachlorobiphenyl  
LBX157LA 
PCB 167 2,3',4,4',5,5'-
Hexachlorobiphenyl  
LBX167LA 
PCB 189 2,3,3',4,4',5,5'- 
Heptachlorobiphenyl  
LBX189LA 
PCB 126 3,3',4,4',5-
Pentachlorobiphenyl 
LBXPCBLA 
PCB 81 3,4,4',5-
Tetrachlorobiphenyl 
LBXTC2LA 
PCB 169 3,3',4,4',5,5'-
Hexachlorobiphenyl 
LBXHXCLA 
 
*The variable named LBX___ provides the analytic result for that analyte. Analytical results 
which were below the detection limit, were automatically divided by the square root of 2 by the 
CDC. Units were originally in ng/g of lipid; except for PCB 126, PCB 81, PCB 169 which were 
originally in pg/g lipid. Their values were converted to ng/g lipid (parts per trillion to parts per 
billion). Also, 562 missing values were removed from the total sample. 
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Appendix III – Phthalates Sampled 
 
Phthalate Metabolites in 2003-2004 NHANES 
 
SAS Name 
for 
Metabolite 
Compound Typical 
Limits of 
Detection 
in PPB 
(NHANES 
Lab 
Manual) 
in ng/mL 
or ppb 
LOD/√2* 
URXECP Mono-2-ethyl-5-
carboxypentyl 
phthalate 
0.25 0.1767766953 
URXMBP Mono-n-butyl 
phthalate 
0.40 
 
0.2828427125 
URXMC1 Mono-(3-
carboxypropyl) 
phthalate 
0.16 0.113137085 
URXMCP Mono-
cyclohexyl 
phthalate  
0.402 0.284256926 
URXMEP Mono-ethyl 
phthalate 
0.264 0.1866761902 
URXMHH Mono-(2-ethyl-
5-hydroxyhexyl) 
0.32 0.22627417 
URXMHP Mono-(2-ethyl)-
hexyl phthalate 
0.90 0.6363961031 
URXMIB Mono-isobutyl 
phthalate 
0.26 0.1838477631 
URXMNM Mono-n-methyl 
phthalate 
1.0 0.7071067812 
URXMNP Mono-isononyl 
phthalate 
1.54 1.088944443 
URXMOH Mono-(2-ethyl-
5-oxohexyl) 
0.45 0.3181980515 
URXMOP Mono-n-octyl 
phthalate 
1.68 1.187939392 
URXMZP Mono-benzyl 
phthalate 
0.072 0.0509116882 
 
*The variable named URX___ provides the analytic result for that analyte. These values were 
divided by the square root of two and manually inserted into the master dataset. Also, 92 missing 
values were removed from the sample. 
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